Upper Gastrointestinal Bleed - Causes, Endoscopic profile and usefulness of Rockall Score. by Rema, Krishnakumar
 UPPER GASTROINTESTINAL BLEED- CAUSES, ENDOSCOPIC 
PROFILE AND USEFULNESS OF ROCKALL SCORE 
 
 
Dissertation submitted in partial fulfillment of the requirements 
for the degree of  
D.M. (MEDICAL GASTROENTEROLOGY) 
Branch – IV 
 
 
 
 
 
 
 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
AUGUST 2008
 
 
ii
CERTIFICATE 
 
 
Certified that this dissertation titled “UPPER GASTROINTESTINAL 
BLEED- CAUSES, ENDOSCOPIC PROFILE AND USEFULNESS OF 
ROCKALL SCORE” is the bonafide record work done by                      
Dr. REMA KRISHNAKUMAR, during the period 2005-08, under my guidance 
and supervision and is submitted in partial fulfillment of the requirement for 
the DM (Branch – IV) Medical Gastroenterology, of The Tamil Nadu Dr. 
M.G.R. Medical University, August 2008 examination. 
 
 
 
The DEAN,                                       
Madras Medical College,                   
Chennai – 3.         
 
Prof. Mohammed Ali, M.D., D.M.  
Professor  & HOD,    
Dept. of Medical Gastroenterology, 
Madras Medical College, Chennai – 3. 
 
 
 
Date & Seal 
 
 
 
 
iii
 ACKNOWLEDGEMENT 
 I thank Dr. T. P. Kalaniti, M.D., Dean, Madras Medical College for 
permitting me to carry out this study and also for providing necessary 
facilities. 
 I am greatly indebted to Prof. Mohammed Ali, D.M, Prof and  Head, 
Department of Medical Gastroenterology , for his guidance, suggestions and 
encouragement.   
 My thanks are due to Prof. P. Padmanabhan, D.M., Additional 
Professor, Department of Medical Gastroenterology for his able guidance and  
support. 
 I express my gratitude to Dr. P. Ganesh, Dr. K. Narayanasamy, Dr. K. 
Premkumar and Dr. Caroline Selvi for their support, interest and enthusiasm 
in completion of this study. 
 I thank my colleagues, Dr. Ramkumar, Dr. P. Mahadevan, Dr. Antony 
Joe, Dr. Karthikeyan and Dr. Gokul for their help and assistance in 
successfully completing this study. 
 I thank my family members who stood by me in successfully 
completing this study. 
 I thank all the patients who cooperated with me in carrying out this 
study, in spite of their illness. This work would be complete and successful, if 
it had contributed, even in the smallest possible way, to alleviate their 
suffering. 
   
 
 
iv
 
CONTENTS 
Chapter Title Page No. 
1. Introduction 1 
2. Aim of the Study 3 
3. Review of Literature 4 
4.  Materials & Methods 41 
5. Results 45 
6. Discussion 59 
7. Conclusion 67 
8. Summary 69 
9. Bibliography 70 
10. Appendix 
i. Proforma 
ii. Master chart 
 
 
 
 
 
 
 
 
 
 
 
 
v
Criteria 
 
Abbreviation Expansion 
Presentation H/M Hematemesis/ Melena 
Severity MN/MD/MS Minor/Moderate/Severe 
Associated 
factors 
A/S/N/C/B Alcohol/Smoking/NSAID/Corrosive/ 
Bleed in past 
Comorbidity C/R/L/O Cardiac/Renal/Liver/ Others 
Timing of 
endoscopy 
E/L Early/ Late 
Endoscopic 
findings 
O/G/D/MW/DU/GU/
MS/A/V/PHTG/ 
PHTD 
Oesophagitis/Gastritis/Duodenitis/ 
Mallory –Weiss tear/Duodenal ulcer/  
Gastric ulcer/ Malignancy/ 
Angiodysplasia/ Varices/Portal 
hypertensive gastropathy/ Portal 
hypertensive duodenopathy 
Risk group A/B/C Low / Moderate/High 
Transfusion B Blood transfusion 
Endotherapy A/EST/EVL Adrenaline/Endoscopic 
Sclerotherapy/ Endoscopic variceal 
ligation 
Rebleed Y Yes 
Mortality D Death 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi
CHAPTER 1 
INTRODUCTION 
Upper gastrointestinal bleeding (UGIB) is a common medical 
emergency associated with significant morbidity and mortality and forms a 
bulk of admissions to medical centres and may encompass many different 
scenarios. A broad spectrum of lesions may be responsible for bleeding from 
the upper gastrointestinal tract; the bleed being massive or trivial and either  
clinically apparent or obscure. 
Gastrointestinal (GI) bleeding is an extremely common clinical problem 
resulting in more than 3,00,000 hospitalizations annually in the United States. 
The overall incidence of upper GI bleeding is approximately 125 
hospitalizations for every 1,00,000 people, with a male to female ratio of 2:1. 1 
Bleeding from upper GI tract is five times as common as lower GI bleed.  
Over the past 45 years, the mortality from upper GI bleeding has 
remained stable at approximately 10%.2 Mortality from acute GI bleeding is 
much greater than that for chronic bleeding. Therefore, it is important to 
understand the pathogenesis of acute GI bleeding, with an emphasis on early 
detection, prevention and intervention, in order to minimize morbidity and 
mortality. 
The clinical presentation reflects the site, etiology and rate of bleeding 
and may manifest in one or more ways. Hematemesis, melena and 
hematochezia are the most common manifestations. The bleeding may be 
obscure in about 5% of cases and at times may manifest as an occult bleed. 
 Peptic ulcers are the most common causes of upper GI bleeding and 
are followed by variceal bleeding, gastric and duodenal erosive disease and 
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Mallory-Weiss tears in prevalence. The associated factors include H. pylori 
infection, NSAID intake and alcohol abuse. 
 An initial hemodynamic assessment helps to plan resuscitation, forms 
the basis of further management and also predicts the prognosis of the 
patient. Analysis of clinical and endoscopic factors permits accurate risk 
assessment, rational treatment planning and improved outcome. 
 Early upper gastrointestinal endoscopy, defined as within 24 hours of 
hospital presentation or admission is the cornerstone of management of 
UGIB. Early endoscopy helps in diagnosis, treatment and risk stratification. 
Therapeutic endoscopy is considered a safe and effective form of treatment 
today. 3  
 A number of scoring systems have been designed to ascertain risk factors for 
poor outcome and to improve patient management and promote cost-effective 
use of hospital resources in patients with UGIB. Rockall et al. developed a 
risk-scoring system involving clinical and endoscopic criteria to predict the risk 
of rebleeding and mortality in patients with UGIB. It is based on age, presence 
of shock, co-morbidity, diagnosis and endoscopic stigmata of recent 
hemorrhage. Multiple studies have validated the Rockall score’s ability to 
identify and risk-stratify patients with UGIB. The Rockall system has been 
shown to represent an accurate and valid predictor of rebleeding and death. 
This has the potential to result in a more appropriate management of subjects’ 
conditions based on their assessed risk of complications following the initial 
UGI bleed. 
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CHAPTER 2 
 
AIM OF THE STUDY 
 
(i) To study predisposing factors, clinical profile and endoscopic 
findings of patients presenting with Upper Gastrointestinal Bleed 
(UGIB) to the   endoscopic unit of our institution 
(ii) To apply Rockall score in the assessment of upper gastrointestinal 
bleed 
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CHAPTER 3 
 
REVIEW OF LITERATURE 
 
Epidemiology 
UGIB is a common reason for emergency admission to hospitals. A 
recent large prospective study from the United Kingdom reported an overall 
incidence of 103 per 1,00,000 adults per year with an overall mortality of 14%, 
but only 0.6% for those below 60 years of age without co-morbidity. Acute 
upper gastrointestinal haemorrhage accounts for about 2500 hospital 
admissions each year in the United Kingdom. The annual incidence varies 
from 47 to 116 (approximately 100) per 1,00,000 population and is higher in 
socioeconomically deprived areas.4 The incidence is approximately 72 per 
1,00,000 population in Malaysia.5,6 A retrospective study from USA also 
showed a similar incidence of 102 per 1,00,000 adults.7  
 The incidence increases markedly with age. Consequently, many 
patients presenting with UGIB have an active comorbid condition, a consistent 
risk factor for increased mortality. Rockall and Logan8 et al. and Yavorski 9 et 
al. noted a mean age of 66 years and 52 years respectively, in their series. 
Longstreth and colleagues10, in their series, noted that 47% of their patients 
were above 60 years of age.  
The incidence of UGIB is twice as high in men as in women.  Barkun et 
al.11 noted that 62% were males. Rockall et al. observed a male 
preponderance of 57%. Longstreth et al. also have noted a male predilection 
of 67.9%. 
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              Hospital mortality has not improved over the past 50 years and 
remains at about 10%.This may in part be due to the fact that older patients, 
who have advanced cardiovascular, respiratory, or cerebrovascular disease 
that puts them at increased risk of death, now comprise a much higher 
proportion of cases. Much of the morbidity and mortality of UGIB occurs in 
patients with recurrent bleeding or significant co-morbid illnesses.12 Figures 
available from a small prospective study from Singapore have showed an 
overall mortality of 10%. 7 
Modes of presentation 
Hematemesis, melena and hematochezia are the most common 
manifestations. 
 Hematemesis is defined as the vomiting of blood and is caused by 
upper gastrointestinal bleed from the oesophagus, stomach or small bowel.  
The blood may be bright red or may take on the appearance of coffee–
grounds. Patients with coffee ground emesis are not usually bleeding actively 
but have had a recent or even remote bleed. 
Melena is defined as passage of black, tarry and foul smelling stools, 
the tarry character being caused by the degradation of blood in the more 
proximal colon and is typical of bleeding from upper GI tract. It is caused by 
delivery of at least 50 ml of blood into the upper gastrointestinal tract and 
indicates that blood has been in the gastrointestinal tract for extended periods 
of time. 
Hematochezia is the passage of bright red blood per rectum that may 
or may not be mixed with stools. 
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Barkun et al. 11 noted hematemesis in 58% of patients and melena in 
69% and Longstreth et al. 10 observed that 33% of their patients had 
hematemesis and 81% had melena. Hematochezia was noted by Barkun et 
al. in 15% and  Laine et al. in 5% of their cases.13 
           Obscure gasrointestinal bleed, is generally accepted to be GI bleeding 
that persists or recurs without an etiology after standard endoscopic 
examination, and occurs in about 5% of patients with GI bleed. 
Occult GI bleeding is taken to mean bleeding that is truly unknown to 
the patient and may manifest with symptoms of blood loss like dizziness, 
dyspnoea, angina or even shock without any objective signs of bleeding. 
Features of iron deficiency anemia or fecal occult blood positivity may be 
present.                       
 
ETIOLOGY OF UPPER GASTROINTESTINAL BLEEDING 14 
NON-VARICEAL CAUSES 
Oesophagus 
• Mallory-Weiss tear  
• Severe oesophagitis 
• Oesophageal ulcer 
• Cameron ulcer within hiatus hernia 
• Oesophageal neoplasm 
• Infections- bacterial, viral and fungal infections  
Stomach 
• Gastric ulcer  
• Gastric erosions  
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• Gastric malignancy  
• Others- gastric polyps, Dieulafoy lesion, angiodysplasia 
Duodenum 
• Duodenal ulcer  
• Duodenal erosions 
• Vascular malformations 
• Aorto-enteric fistula 
• Polyps (including Peutz- Jeghers syndrome and other polyposis 
syndromes)  
• Carcinoma of ampulla, carcinoma of pancreas, haemobilia 
Small bowel 
• Stomal ulcer 
• Diverticulae (including Meckel’s diverticulum) 
• Vascular malformation, tumours 
 Bleeding caused by portal hypertension 
• Varices 
• Nonvariceal mucosal lesions- portal hypertensive gastropathy, 
gastric antral vascular ectasia 
 
Peptic ulcer disease 
Peptic ulcer disease accounts for 50% to 70% of cases of acute 
nonvariceal upper GI bleeding .15, 16   
Ulcer bleeding starts when the ulcer base erodes into a blood vessel, 
and the severity of the bleed is dependent on the size of the vessel affected. 
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Simple oozing is caused by damage to small submucosal vessels less than 
0.1 mm in diameter and more severe arterial bleeding indicates that  a large  
vessel between 0.1 and 2 mm in diameter in the base of the ulcer has been 
eroded by the inflammatory process. Large ulcers arising from the posterior 
part of the duodenal cap can erode the gastroduodenal artery and provoke 
brisk bleeding. 
Spontaneous hemostasis occurs when a sentinel clot plugs the “side 
hole” in the vessel. The clot may then enlarge, remain attached for some time 
as it organizes, and eventually sloughs off, leaving the underlying vessel 
covered with a flat pigmented spot that fades to leave a clean ulcer base This 
process takes less than 72 hours, and rebleeding occurs if the clot undergoes 
lysis or falls off prematurely.17 
Even though ulcer bleeding stops spontaneously in at least 80% of 
patients,  the overall mortality is unchanged over the last 30 years, ranging 
from 6 to 7% in the United States 13 and averaging 14% in the United 
Kingdom.18 Without specific hemostatic intervention, peptic ulcer bleeding 
continues or recurs in approximately 20% of patients.  
Erosions 
Acute erosive gastritis can cause persistent haemorrhage as a result of 
diffuse loss of mucosal epithelium and is often associated with the use of non-
steroidal anti inflammatory drugs, steroids and intake of alcohol. 
Haemorrhagic gastritis occurring as a result of impaired mucosal blood flow is 
often caused by stressful stimuli including shock, hepatic failure and head 
injury. 
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Oesophagitis usually only causes minor acute bleeding. Occasionally a 
significant vessel may be involved with consequent massive arterial 
hemorrhage.  
Mallory-Weiss Tear 
Mallory-Weiss lesions are tears occurring at or near the 
esophagogastric junction, secondary to mechanical stress most commonly 
induced by vomiting and increased intra abdominal pressures during retching. 
Mallory-Weiss lesions account for 4–14% of all cases of acute upper GI 
bleeding in patients who undergo endoscopy.19 Most  series report a male 
predominance of 60–80%.20 with mean age typically in the fourth to sixth 
decades. Recent alcohol ingestion has been reported in 21–80% of cases. 
Any condition causing vomiting could produce a tear, including coughing and 
pregnancy. 
The diagnosis of Mallory-Weiss lesions is best made endoscopically 
with close inspection of the gastro-oesophageal junction. The lesion is 
longitudinal, most commonly along the cardia, extending proximally to include 
the distal esophagus. Occasionally, repeated vomiting may result in a full 
thickness tear (Boerhaave’s syndrome) which is associated with sudden onset 
of severe pain in the upper abdomen or chest. 
The bleeding associated with Mallory-Weiss lesions is usually self 
limited, with spontaneous cessation of bleeding reported in 90% of cases. 20 
Protracted bleeding can rarely occur. 
Malignancy 
Carcinoma and lymphoma of the stomach commonly bleed at an 
advanced ulcerated stage, and occasionally present with acute hemorrhage. 
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RISK FACTORS 
 Gastric Acid 
The evidence for a role of gastric acid in peptic ulceration includes the 
hypersecretory disorder Zollinger-Ellison syndrome, in which patients develop 
ulcers with high frequency. 21The ability of antacid therapy alone to heal upper 
gastroduodenal tract ulceration also supports the role of acid. Acid reduction 
by proton pump inhibitors in patients with active or recent bleeding from upper 
gastrointestinal ulcerative lesions reduces the risk of bleeding and 
rebleeding.22 
Aspirin and other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
Approximately 15-30% of patients exposed to NSAIDs develop 
gastroduodenal ulcers. The mechanism of injury and ulceration is complex but 
appears to involve reduced production of cytoprotective prostaglandins. 
Further, the risk of bleeding is increased in part because of platelet 
dysfunction.  
The following points appear to be of note:  
(1) The risk for gastric ulceration is greater than that for duodenal 
ulceration, although both are increased  
(2) The risk of bleeding varies with the individual NSAID 
(3) The risk of bleeding is dose dependent  
(4) Multiple cofactors contribute to NSAID risk 
• Age greater than 75 years  
• History of heart disease  
• History of peptic ulcer  
• History of previous gastrointestinal bleeding  
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In addition, H. pylori may be a risk factor for ulcers. Corticosteroids, 
bisphosphonate (alendronate), and ethanol appear to potentiate the 
ulcerogenic effect of NSAIDs. Any dose of aspirin has the potential to cause 
gastrointestinal bleeding, the enteric-coated form carrying the same risk as 
plain aspirin .24 
Helicobacter pylori 
H. pylori(HP) is a gram negative bacteria whose motility and adherence 
mechanisms allow it to colonize the stomach despite ongoing gastric motility. 
The most dominant feature of HP is its ability to tolerate the stomach 
environment with its acidic pH, constant emptying and rapidly exchanging 
epithelial layer. Prevalence rates are higher in developing countries, and in 
these areas, infection is much more common in the young. 
         Role of H. pylori in ulcer bleeding is controversial. Studies have 
suggested that H. pylori infection increases the likelihood of hemorrhage 
(relative risk, approximately 1.5).25In contrast, one study revealed a 
decreased incidence of H. pylori infection in patients presenting with actively 
bleeding ulcers.26 
       The role of H. pylori infection in causing hemorrhage of ulcers in those 
using NSAIDs is also controversial. On one hand, NSAID users infected with 
H. pylori had a nearly twofold risk of ulcer bleeding compared with uninfected 
NSAID users. In contrast, other studies have suggested that H. pylori has little 
adverse effect or may even protect against NSAID–associated 
gastroduodenal lesions and promote ulcer healing. The eradication of H.pylori 
substantially reduces the risk of ulcers for patients who are about to start long-
term NSAID therapy. 27  
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  Techniques to diagnose HP infection, such as serologic testing and 
histologic analysis, require several days for confirmation and may not be 
useful in the setting of acute bleeding. Only 2 tests are available to rapidly 
assess HP infection, the CLO (rapid urease) test and carbon 14 urea breath 
analysis. The breath analysis is not uniformly available in many institutions. 
Further, data suggest that in those undergoing endoscopy for active bleeding, 
the CLO test lacks sensitivity with a substantial false-negative rate. Lee et 
al.23 analyzed the diagnosis of HP infection in 55 patients with bleeding 
duodenal ulcers and compared results with 69 patients with uncomplicated 
ulcers. A variety of diagnostic methods to assess HP infection were used 
including the CLO test, serologic analysis, and microbiologic and histologic 
evaluation. The false negative rate with the CLO test was significantly higher 
in those with bleeding ulcers vs those without (18.2% vs 1.4%; P<.05). They 
further noted that those with bleeding ulcers had HP infection rates 
significantly lower than those with uncomplicated disease (72.7% vs 92.8%; 
P<.05). These data would suggest that in the absence of breath analysis, a 
rapid and reliable method to diagnosis HP infection in those with bleeding 
ulcers is lacking. 
Ethanol 
Ethanol is well known to induce gastric mucosal injury and thus may 
cause or potentiate ulcer bleeding. Deleterious effects of NSAIDs are further 
increased among drinkers. Patients who ingest ethanol chronically may have 
alcohol-induced liver disease and secondary portal hypertension, which is an 
important risk factor for non ulcer upper gastrointestinal hemorrhage.  
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Anticoagulation Therapy 
Anticoagulation increases the risk of bleeding from ulcer disease. The 
relative risk of hospitalization for bleeding ulcer in anticoagulated patients is 
about 3, and anticoagulants further increase the risk of bleeding in those 
taking NSAIDs. 28 
 Longstreth et al.10 noted history of NSAID use in 53% and alcohol use 
in 3% of patients, in their series. 
BLEEDING FROM PORTAL HYPERTENSION 
Portal hypertension may lead to bleeding from several different lesions, 
including esophageal varices, gastric varices, ectopic varices, portal 
hypertensive gastropathy and portal hypertensive duodenopathy. 
VARICES  
 Oesophageal varices  
 They appear as serpentine venous channels that course through 
several levels from the lamina propria to the deep submucosa of the 
oesophagus, achieve their greatest prominence, as a rule, 2 to 3 cm above 
the gastro-oesophageal junction, and in time may extend cephalad to the mid-
oesophagus(usually upto 24 cm from incisor teeth). Rupture of oesophageal 
varices is a common cause of life threatening hemorrhage.  
Gastric varices  
The next most common site for the formation of clinically significant 
varices is the stomach, either in obvious continuity with oesophageal varices, 
that is, true gastro-oesophageal varices, or as free-standing gastric varices. 
Various classifications for the different locations of gastric varices have been 
proposed. According to Sarin et al 30, gastro-oesophageal varices type I (GOV 
 
 
xix
I)are those that appear as an inferior extension of oesophageal varices; type II 
are isolated gastric varices(IGV) in the fundus or body and antrum of the 
stomach without esophageal varices.29,30 GOV are further subdivided into 
GOV1( extending along the lesser curvature) or GOV2 ( extending along the 
greater curvature towards fundus of stomach)  Similarly, IGV have been 
divided into IGV1(located in gastric fundus) and IGV2( located in antrum, body 
and pylorus). GOV1 is the most common variant, accounting for 74%, 
followed by GOV2 (16%), IGV 1(8%) and IGV2 (2%).   
Gastric Varices
74
16
8 2
GOV1
GOV2
IGV1
IGV2
           
Fig 1.Sarin’s classification of gastric varices 
 
The appearances of gastric varices vary from a relatively subtle, bluish 
discoloration of otherwise normal appearing gastric mucosal folds to more 
obvious, classic cerebriform clusters of veins. The largest study to date found 
gastric varices in 20% of patients who had portal hypertension from a variety 
of causes.30 Factors that promote the formation of gastric varices are poorly 
understood. Gastric fundal varices in the absence of oesophageal varices 
should raise the suspicion of splenic vein thrombosis, although in most cases  
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fundal varices are simply a manifestation of portal hypertension caused by 
cirrhosis. 
Nonvariceal mucosal Lesions 
Portal hypertension is associated with a widespread abnormality in 
gastrointestinal mucosal microcirculatory integrity. Portal hypertensive 
gastropathy is a common finding in patients who have portal hypertension.31 
Here, there is evidence for increased gastric mucosal blood flow .32 Although 
previous sclerotherapy has been noted by some authors to increase the risk 
of gastropathy 31, there is little agreement on this point. 33 
Portal hypertensive gastropathy is often graded by endoscopic 
appearance from mild to severe, with mild gastropathy characterized by a 
mosaic or "snakeskin" pattern of erythema and severe gastropathy by a 
variety of morphologic characteristics including bright red punctate erythema, 
diffuse hemorrhagic lesions, and black or brown spots indicating submucosal 
hemorrhages. Portal hypertensive gastropathy accounts for 8% to 20% of 
acute bleeding in patients who have portal hypertension and also has been 
identified as an important source of chronic blood loss. 33 
Gastric antral vascular ectasia (GAVE), or "watermelon stomach," may 
occur with increased frequency in cirrhosis and portal hypertension (40%). 
The lesion may be confused with portal hypertensive gastropathy but shows 
little relation to portal hypertension and is not ameliorated by portal 
decompressive procedures.34 
  Large national surveys have reported that about 10% of patients with 
UGIB bleed from varices35 whereas in inner city hospital populations, 
approximately one third of patients bleed from varices.36 
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Rockall and Logan 8 studied 2332 cases of UGIB, taking into 
consideration both variceal and non variceal etiology of bleed and the various 
causes included peptic ulcer-842(36.1%), erosive gastritis-240(10.3%), 
oesophagitis-241(10.3%), Mallory-Weiss tear-119(5.1%) ,malignancy- 93(4%)  
and varices -108(4.6%) 
Barkun et al. 11 noted in their study based on RUGBE database, that 
56% had peptic ulcers disease as the primary etiology for UGI bleeding, 
followed by oesophagitis (8.4%), Mallory- Weiss tears(4.4%) and Dieulafoy 
lesions(2.5%) 
INITIAL PATIENT ASSESSMENT 
The first step in treating all patients with gastrointestinal bleeding is to 
assess the severity of bleeding. Therefore, hemodynamics is the initial focal 
point, helping to focus resuscitation efforts and predicting prognosis. 
Resuscitation 
 Airway 
A drowsy or comatose patient is at high risk of aspiration if vomiting or 
hematemesis continues. The patient is kept flat on his/her side. A cuffed 
endotracheal tube may be inserted to protect the airway if needed. 
 Mental status may be impaired due to 
1. Cerebral hypoperfusion due to severe acute blood loss 
2. Encephalopathy due to concomitant chronic liver disease or renal 
failure 
3. Alcohol or drug intoxication/overdose  
When a patient presents with gastrointestinal bleeding, risk assessment and 
resuscitation should proceed simultaneously. The first step in management 
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should be to assess the severity of bleeding. Upper GI bleed can be 
categorized into minor, moderate or major, depending on hemodynamic 
assessment. 37 
Table 1. Severity of bleed 
Vital signs   Loss of intravascular 
volume (%) 
Bleed type 
Shock 
(resting hypotension) 
20-25 Massive 
Postural 
(orthostatic tachycardia or hypotension) 
10-20 Moderate 
Normal 
 
<10      Minor 
 
This categorization forms the basis of further management, focuses 
rescuscitation efforts, provides important prognostic information and helps 
triage appropriate intervention. 
In patients with hemodynamic instability, two large bore IV catheters 
should be placed, normal saline or Ringer lactate solution infused along with 
packed cell transfusions to raise hematocrit to 30% in elderly and 27-28% in 
those with portal hypertension. Supplemental oxygen should be given along 
with monitoring of central venous pressure, vital signs and urine output.  
History and examination 
  The history helps the clinician assess the severity of bleeding and 
make a preliminary assessment of the site and cause of bleed.  
Physical examination may reveal the presence of cutaneous signs 
(spider angiomata, Dupuytren's contracture) or other evidence of liver disease 
(splenomegaly, ascites, caput medusae), that suggest the possibility of portal 
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hypertension. Acanthosis nigricans may reflect underlying gastric cancer; 
cutaneous telangiectasias of skin and/or mucous membranes and lips may 
point to hereditary hemorrhagic telangiectasias (Osler-Weber-Rendu 
syndrome); pigmented lip lesions are seen with Peutz-Jeghers syndrome; 
cutaneous tumors suggest neurofibromatosis; purpura is consistent with 
vascular disease (Henloch-Schönlein purpura or polyarteritis nodosa).  
Abdominal tenderness (peptic ulcer, pancreatitis, ischemia), abdominal 
masses, lymphadenopathy (malignancy), and splenomegaly (cirrhosis, splenic 
vein thrombosis) are all important to detect, in a case of UGIB. 
Bedside examination of the character of the stool provides critical 
information not only about the site of bleeding, but also about the acuity of 
bleeding. Patients with brown stools are unlikely to have aggressive bleeding. 
In contrast, patients who are actively passing stools containing red blood, 
maroon-colored blood, or melena even in the absence of a positive 
nasogastric lavage; are likely to have active bleeding. Those with a history of 
coffee ground emesis only and normal-appearing stools, often positive for 
occult blood, have usually had a trivial bleed. 
The blood urea nitrogen (BUN) level may be mildly elevated in patients 
with upper Gl bleeding. The elevation is typically out of proportion to elevation 
in the serum creatinine level 38 due to breakdown of blood proteins to urea by 
intestinal bacteria and its absorption, as well as from a mild reduction in 
glomerular filtration rate. 
The nasogastric lavage has been used extensively to help differentiate 
upper from lower gastrointestinal bleeding. 27 A bloody aspirate confirms the 
upper gastrointestinal tract as the source of bleeding, since the false-positive 
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rate is essentially nil and is related to nasogastric trauma.The correlation 
between the acuity of bleeding and the physician’s assessment of bleeding is 
weak, with a 79% sensitivity and 55% specificity for active bleeding. It is 
negative in up to 25% of patients with upper gastrointestinal bleeding.  
RISK STRATIFICATION 
At the initial assessment it is important to define the factors that have 
prognostic importance. 
Risk factors for death after hospital admission for acute upper 
gastrointestinal bleeding 18 
1. Advanced age 
2. Shock on admission (pulse rate >100 beats/min; systolic blood 
pressure < 100 mm Hg) 
3. Comorbidity (particularly hepatic or renal failure and disseminated 
malignancy) 
4. Diagnosis (worst prognosis for advanced upper gastrointestinal 
malignancy) 
5. Endoscopic findings (active, spurting haemorrhage from peptic ulcer; 
non-bleeding visible vessel) 
6. Rebleeding (increases mortality about 10 fold) 
The main factors predicting death include increasing age, comorbidity 
and endoscopic findings. Mortality is low in patients below 40 years of age but 
increases steeply thereafter. Patients with severe comorbidity, particularly 
renal failure, liver failure and disseminated malignancy have a poor prognosis. 
Death in these patients is more often due to disease progression rather than 
due  to the upper gastrointestinal bleeding. Patients who developed UGIB 
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after hospitalisation for other serious illnesses have a much worse prognosis 
than those who are admitted because of bleeding, with a mortality of about 
30%. 
Endoscopy for risk assessment 
Endoscopy is the most accurate method available for identifying the 
source of bleeding and providing therapy in UGIB. A large double or single 
channel therapeutic endoscope should be used in all suspected cases of 
upper GI bleed.Positioning the patient with bleeding point in the most superior 
position can help clear the endoscopic field by allowing blood to flow away 
from the point of bleeding. Reverse Trendelenberg positioning and rolling 
patient from left lateral decubitus position to the back can also be used to 
move clots away from dependent areas of the stomach.  
Early upper gastrointestinal endoscopy , defined as within 24 hours of 
hospital presentation or admission; is the cornerstone of management of 
UGIB. Early endoscopy has 3 major roles viz. diagnosis, treatment and risk 
stratification. It has been shown to reduce resource use, decrease transfusion 
requirements and shorten hospital stay. Chak et al. observed that early 
endoscopy was done in 82% of their patients.39 Rockall et al. noted that 
1108(50.1%) of their patients underwent early endoscopy. Longstreth et al. 
suggested that early endoscopy is an important factor in shortening duration 
of hospital stay, identifying patients for outpatient care and reducing costs in 
upper GI bleed. Lee et al. stated that early endoscopy was most accurate in 
determining the source of bleeding and reduced transfusion requirements and 
length of hospital stay. 
 
 
xxvi
Endoscopic findings of active, spurting haemorrhage and a non-
bleeding visible vessel within an ulcer are associated with a definite risk of 
rebleeding. The absence of these stigmata, varices or upper gastrointestinal 
cancer indicates a low risk of rebleeding. Ulcers located in postero-inferior 
portion of duodenal bulb and high on lesser curvature of the stomach, have a 
poor prognosis. 
Forrest Classification for Bleeding Peptic Ulcer 40 has been 
formulated, which helps to plan endoscopic treatment and assess risk of 
rebleed.  
The classification is as follows 
IA: Spurting Bleeding 
IB: Non spurting active bleeding 
IIA: visible vessel (no active bleeding) 
IIB: Non bleeding ulcer with overlying clot (no visible vessel) 
IIC: Ulcer with pigmented spot 
III: Clean ulcer base (no clot, no vessel)  
Laine et al.13  noted, in their series  that  Forrest class I ulcers 
constituted 18%, Forrest IIA and B ulcers were found to contribute to 17% 
each, IIC ulcers constituted 20% and Forrest class 3  ulcers, constituted a 
majority (  42%). 
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Risk of rebleeding and mortality  
Peptic Ulcer Bleed13  
Table 2.Forrest class and risk of bleeding 
Endoscopic finding 
 
Risk of Rebleeding (%) Mortality (%) 
 
Active bleeding 55 11 
Visible Vessel 43 11 
Adherent Clot 22 7 
Flat Spot 10 3 
Clean Base 5 2 
 
 Variceal bleed  
The stigmata of recent hemorrhage(SRH) include red colour signs 
which  include red “wale” markings, which are longitudinal whip-like marks on 
the varix; cherry-red spots, which usually are 2 to 3 mm or less in diameter; 
hematocystic spots, which are blood-filled blisters 4 mm or greater in 
diameter; and diffuse redness Patients with large oesophageal varices, Child-
Turcotte-Pugh (CTP) class C cirrhosis, and red colour signs on varices have 
the highest risk of variceal bleeding within 1 year. 
Recently, a number of studies have indicated that systematic 
assessment of clinical and endoscopic risk factors (endoscopic triage) may 
obviate hospitalisation in some patients and may help in determining the 
appropriate length of stay in others. 10, 41, 42 Those determined to be at low-risk 
based on clinical and endoscopic criteria were discharged on the day of 
presentation and received out-patient care. 43, 44 The aforementioned findings 
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have led to the development of practice guidelines and clinical care pathways 
for UGIB. 45, 46  
Use of Risk Stratification Scoring Systems 
Although endoscopic findings can identify individuals at a high risk of 
rebleeding, overall mortality is often reflective of other factors such as age and 
co-morbid conditions. A number of scoring systems have been designed to 
ascertain risk factors for poor outcome and to improve patient management 
and promote cost-effective use of hospital resources in patients with UGIB. 
           Several clinical scoring systems e.g. Rockall score, Baylor 
bleeding score, the Cedar-Sinai Medical Centre Predictive Index and the 
Blatchford score, have been developed to direct appropriate patient 
management and enable cost effective use of resources. These systems 
weigh a combination of clinical, laboratory and endoscopic variables to 
produce a score that predicts the risk of mortality, recurrent haemorrhage, 
need for clinical intervention or suitability for early discharge.  
Risk stratification using non endoscopic parameters has the advantage 
that it can be performed readily on initial presentation in the emergency 
department and appropriate initial risk assessment is still possible, even if 
early endoscopy, which requires skilled staff and resources, is not always 
available. Inclusion of endoscopic stigmata of recent hemorrhage (SRH) that 
relate to increased risk of re-bleeding and death into scoring systems 
increases the sensitivity for predicting patients at high or low risk compared to 
non-endoscopic assessments.40, 42, 47 High risk lesions such as actively 
bleeding ulcers, non-bleeding visible vessels (NBVV) and adherent clots 
require effective aggressive intervention to reduce re-bleeding which is 
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associated with a 5-16 fold increase in mortality.13,18 The rebleeding rate of 
ulcers with a clean base is  low and endoscopic intervention is usually not 
recommended48,49 In fact, early endoscopy-based triage may permit safe and 
early discharge of “low risk” patients with no increased rate of re-bleeding or 
mortality.50  
 Rockall et al 18 conducted a prospective, multicentre, population based study 
using standardized questionnaires in two phases one year apart. A total of 
4185 cases of acute upper gastrointestinal hemorrhage over the age of 16, 
identified over a four month period in 1993 and 1625 cases identified 
subsequently over a three month period in 1994 were included in the study. It 
was found that age, shock, co-morbidity, diagnosis, major stigmata of recent 
haemorrhage, and rebleeding were all independent predictors of mortality 
when assessed using multiple logistic regression. A numerical score using 
these parameters has been developed that closely follows the predictions 
generated by logistical regression equations. When tested for general 
applicability in a second population, the scoring system was found to 
reproducibly predict mortality in each risk category 
The Rockall risk score is a simple, validated predictive index that may 
serve as a useful clinical decision rule for assessing the risk of subsequent 
adverse outcomes in patients with UGI bleed. 51 An initial Rockall score based 
on clinical variables (age, shock, and co-morbidity) can range from 0 to 7 
points. A complete score takes into account the endoscopic lesion 
categorization and stigmata of hemorrhage and can range from 0 to 11 points. 
For example, using the criteria described above, if a subject less than 60 
years of age, with no co-morbidity, was found to have a Mallory-Weiss tear 
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and no stigmata of recent hemorrhage during endoscopy, he /she  would have 
a total Rockall score of 0.  
Table 3. Rockall Scoring system  
Rockall Score 
Variable 0 1 2 3 
Age (y) <60 60-79 >80  
Shock No Shock (Systolic 
BP >100 mm Hg; 
pulse <100 
beats/min) 
Tachycardia 
(Systolic BP >100 
mm Hg; pulse 
>100 beats/min) 
Hypotension 
(Systolic BP <100 
mm Hg; pulse <100 
beats/min) 
 
Co 
morbidity 
None - Cardiac failure, 
Ischemic heart 
disease, any major 
co morbdity* 
Renal failure, 
liver failure, 
disseminated 
malignancy 
Diagnosis Mallory-Weiss, no 
lesion or stigmata of 
recent hemorrhage 
All other diagnosis Malignancy of the 
upper GI tract 
- 
SRH None or dark spot - Blood in upper GI 
tract, adherent clot, 
visible or spurting 
vessel 
- 
*Any major comorbidity would be defined as any other immediately unstable life threatening illness in 
addition to cardiac failure, IHD, renal/liver failure and cancer etc. (Rockall et al., 1996) 
 
The patients were classified into three risk groups, based on the 
Rockall score. Those with a score less than 3 fell into group A (low risk), score 
of 3-5 were placed in group B (moderate risk) and those with a score of 6 or 
more in group C (high risk).                 
For cases with a score of less than three, several studies suggest that 
rebleed  occurred in less than 5% of patients and death occurred in less than 
1% of patients 52,53,54 , but a score in excess of 8 is associated with a 41% 
mortality and rebleeding rate of 42.1%. 
Rockall et al. noted that 45.4% of their patients belonged to the low risk 
group, 50.7% to the moderate risk and 3.9% to the high risk group and the 
percentage of rebleed progressively increased from the low risk (8.8%) to the 
high risk groups (17%)  Barkun et al. based on data from the RUGBE 
database, found that 13% , 53% and 34% belonged to low, moderate and 
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high risk groups respectively, with a higher percentage, belonging to the high 
risk group, as compared to that noted by Rockall et al.    
Overall rebleed rates of 13.8% were noted by Barkun et al.1 Rockall et 
al found it to be 15.4% but Yavorski et al observed a much lower rebleed rate  
of 7.1%. 
Comorbidities were noted by Rockall et  al in  59.1%,and Yavorski et al  
in 50.9%.9 and hemodynamic instability was noted by Rockall et al. in 
11.2%.Yavorski et al.9 noted that blood transfusions were instituted in 47.3% 
of their cases. 
The Rockall system has been shown to represent an accurate and 
valid predictor of rebleeding and death. This score can be used to compare 
outcomes in audit and research and to calculate risk standardised mortality. 
This has the potential to result in a more appropriate management of subjects’ 
conditions based on their assessed risk of complications following the initial 
UGI bleeding. 
In addition, this risk score can identify 15% of all cases with acute 
upper gastrointestinal hemorrhage at the time of presentation and 26% of 
cases after endoscopy, who are at low risk of rebleeding and negligible risk of 
death and who might therefore be considered for early discharge or outpatient 
treatment with consequent saving of resources. Such risk assessment scores 
may be useful in triaging patients for either outpatient care or admission to a  
high dependency unit.  
Among these studies, Sanders et al. 53 prospectively studied 325 
patients admitted to a specialized hemorrhage unit over a 3-year period. The 
aim of their study was to assess the validity of the Rockall risk-scoring system 
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in predicting rebleeding and mortality in subgroups of patients with 
esophageal varices or peptic ulcers. The results of their study were 
comparable to those of Rockall’s initial cohort in predicting rebleeding and 
death in patients with either ulcers or varices (scores of < 3 accounted for 
29.4% of patients, of whom only 4.3% rebled and 0.1% died).  
Enns et al.55 noted that Rockall scoring system has a good 
discriminative ability and provides an acceptable tool to predict death, but 
performs poorly for endpoints of rebleeding and surgical procedures. 
Vreeburg et al. 54 concluded that the risk scoring system developed by 
Rockall and coworkers is a clinically useful scoring system for stratifying 
patients with acute UGIB into high and low risk categories for mortality. For 
the prediction of rebleeding, however, the performance of this scoring system 
was unsatisfactory. 
  Dulai et al.51 conducted a retrospective study to accurately risk stratify 
patients by using the Rockall score. Their findings suggested that a significant 
number of all patients hospitalized with acute UGIB are at low risk of adverse 
outcomes related to their hemorrhage episodes.  
Oei and colleagues 52 evaluated and compared the incidence of low-
risk UGIB admissions, adverse outcomes, and the levels of healthcare 
resource use in a community hospital and a university hospital. The data from 
their study confirmed the low rate of morbidity and mortality in both practice 
settings, suggesting that downgrading the site of initial admission for low-risk 
patients with early discharge could conserve healthcare resources without 
compromising patient safety.  
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In a study by Akash et al. 56 from Chennai, Rockall score was found to 
correlate well with clinical outcome including rebleeding and mortality.   
These studies demonstrate that patients with a low Rockall score can 
be managed safely as outpatients, or with limited admission and early 
discharge, without adversely influencing patient outcomes and with 
considerable resource savings. 
Blatchford and colleagues.42 developed and tested a simple scoring system to 
identify patients at high or low risk of requiring hospital admission and 
aggressive treatment to control gastrointestinal bleeding. They studied 1748 
patients admitted with upper GI bleed and used logistic regression in the 
derivation of risk score. This scoring system does not require endoscopic 
evaluation to aid risk stratification 
 Table 4. Blatchford scoring system 
Risk marker Score 
component
value 
Risk marker Score 
component
value 
Blood urea nitrogen--mg per dL (mmol per L)   Systolic blood pressure-mm Hg  
≥18.2 and <22.4 (≥6.5 and <8.0 )   2 100 to 109 1 
≥22.4 and <28.0 (≥8.0 and <10.0)  3 90 to 99 2 
≥28.0 and <70.0 (≥10.0 and <25.0)   4 <90 3 
≥70.0 (≥25)  6 Other markers  
Hemoglobin in men--g per dL (g per L)   Pulse >=100 per minute 1 
≥12.0 and <13.0 (≥120 and <130)  1 Presentation with melena 1 
≥10.0 and <12.0 (≥100 and <120)   3 Presentation with syncope 2 
<10.0 (<100)  6 Hepatic disease  2 
Hemoglobin in women--g per dL (g per L)   Cardiac failure  2 
≥10.0 and <12.0 (≥100 and <120)   1    
<10.0 (<100)  6     
 
The Baylor Group developed and validated the Baylor Bleeding Score 
to identify patients who might require early surgical intervention.57 By 
assessing simple pre-endoscopic (age; number and severity of concurrent 
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medical illnesses) and post-endoscopic parameters (site and stigmata of 
bleeding ulcers), Saeed et al. showed that this scoring system might be able 
to predict patients at risk of rebleeding after successful endoscopic therapy of 
bleeding ulcers.  
APACHE II scoring system has been used in measuring the severity of 
acute illness and Schein and Gecelter 58 noted that among 96 patients 
operated for bleeding peptic ulcers, none of the patients with a score of less 
than 11 died, whereas the mortality in those who scored more than 10 was 
22%, thus indicating its usefulness in predicting outcome in these patients.   
 
ACUTE NON-VARICEAL UPPER GASTROINTESTINAL BLEED 
Pharmacological management 
  If the gastric pH is maintained above 6 (by infusional PPI), platelet   
aggregation is optimized and fibrinolysis relatively inhibited, thereby 
potentially improving the likelihood of clot stability at the ulcer site. Individual 
trials of H2 receptor antagonists (H2RA) have generally failed to demonstrate 
a clinical benefit in UGIB. 
Several studies have evaluated intravenous proton pump inhibitors 
(PPI) for non-variceal UGIB; in the usual intravenous 80mg bolus dose  
followed by a continuous infusion of 8mg/hour for up to 72 hours and this has  
now shown a benefit in terms of re-bleeding, need for surgery and  mortality.59 
Proton pump inhibitors have been advocated, by ASGE, prior to endoscopy, 
for bleeding peptic ulcers and in suspected peptic ulcer bleeds.  
 
 
xxxv
Bolus administration of intravenous erythromycin prior to endoscopy 
has been shown to clear the stomach of blood, increases the likelihood of 
successful haemostasis and reduces the need for subsequent interventions.60  
The usefulness of somatostatin and its analogue, octreotide, is a matter of 
debate.61 
TREATMENT OF ULCERS IN NSAID USERS 
Proton pump inhibitors are superior to H2RAs and misoprostol for 
healing NSAID ulcers in the setting of continued NSAID use. In the “Acid 
Suppression Trial: Ranitidine versus Omeprazole for NSAID Associated Ulcer 
Treatment” (ASTRONAUT) study, 541 patients with ulcers or extensive 
erosions were randomized to omeprazole 20 or 40 mg or ranitidine 150 mg 
twice daily. After 8 weeks of treatment, the rates of healing in all types of 
lesions were higher in those treated with omeprazole compared with 
ranitidine. The higher dose of  proton pump inhibitor was not superior to  lower 
dose 62 and similar data exist for other proton pump inhibitors.63 In the 
“Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management” 
(OMNIUM) study, in which 900 NSAID using patients with ulcers or extensive 
erosions were randomized to receive misoprostol 200 μg 4 times a day or 
omeprazole 20 or 40 mg once daily for 8 weeks, gastric ulcer healing was 
significantly more frequent on 20 mg of omeprazole compared with 
misoprostol. The rates of duodenal ulcer healing were also significantly higher 
in the groups given omeprazole 20 or 40 mg compared with misoprostol.64 
                   If the patient can discontinue the NSAID, all forms of anti-ulcer 
therapy work effectively. The standard of care remains that all patients with 
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peptic ulcer disease, whether taking NSAIDs or not, undergo testing for and 
treatment of H. pylori infection. 
Treatment of H. pylori infection 
Two Antibiotics Plus One Adjunctive Agent (Triple Therapy)  
Triple therapy with either bismuth or a PPI combined with two 
antibiotics is now the most widely used regimen. Therapy with bismuth, 
metronidazole, and tetracycline (“traditional” triple therapy) produces very 
good cure rates, especially with organisms sensitive to metronidazole. 
Substitution of clarithromycin for metronidazole gives similar results.65 The 
most popular triple therapy combines a PPI with two of these three 
antimicrobials: amoxicillin, metronidazole and clarithromycin. 
Two Antibiotics Plus Two Adjunctive Agents (Quadruple Therapy)  
This consists of metronidazole (500 mg three times daily), tetracycline 
(500 mg three or 4 times daily), bismuth subsalicylate or subcitrate (three or 
four times daily) and a PPI twice daily.  
THERAPEUTIC STRATEGY  
The most effective regimens to cure H. pylori infection are 
combinations of two antibiotics and adjunctive agents taken for 14 days. The 
most effective and best tolerated combination seems to be a twice-a-day 
combination of 1000 mg of amoxicillin and 500 mg of clarithromycin (PPI + 
AC) or 500 mg of metronidazole and either 250 or 500 mg of clarithromycin 
(PPI + MC).  
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ENDOSCOPIC THERAPY 
Endoscopic therapy has been shown to improve outcome in 
nonvariceal haemorrhage. In a recent meta-analysis of 30 randomized trials 
involving more than 2000 patients, endoscopic therapy reduced rates of 
further bleeding, need for urgent surgery  and mortality. 66 
Endoscopic therapy is indicated when there are major stigmata of 
recent haemorrhage (SRH). There is little doubt that Forrest IA, IB and IIA 
ulcers should have endoscopic hemostasis. 67 Patients with an adherent clot 
may also constitute a high-risk group. Up to one-third of blood clots covering 
an ulcer can be removed to reveal major stigmata of recent hemorrhage. 
Current opinion favours the displacement of the clot by irrigation or 
mechanical removal, followed by endoscopic hemostasis of any underlying 
visible vessel. Forrest IIC and III ulcers may be managed conservatively and 
discharged early.  
Several endoscopic therapies have been described in the treatment of 
actively bleeding Mallory-Weiss lesions and have included endoscopic 
electrocoagulation, epinephrine injection or heater probe cauterization. 
ENDOSCOPIC TREATMENT FOR NON-VARICEAL UPPER 
GASTROINTESTINAL BLEEDING- VARIOUS MODALITIES 51 
1. Thermal 
a. Heater probe 
b. Multipolar electrocoagulation (BICAP,  Gold Probe) 
c. Argon plasma coagulation 
d. Laser 
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2. Injection 
a. Adrenaline (1:10000) 
b. Procoagulants(fibrin glue,human thrombin) 
c. Sclerosants (ethanolamine, 1% polidocanol) 
d. Alcohol (98%) 
3. Mechanical 
a. Clips 
b. Band Ligation 
c. Endoloops 
d. Staples 
e. Sutures 
4. Combination therapy 
a. Injection plus thermal therapy 
b. Injection plus mechanical therapy  
Recent focus has been directed towards combination therapies and 
mechanical means of homeostasis and it has been suggested as the 
recommended line of management by international and ASGE guidelines.  
Injection therapy 
Injection of dilute (1:10,000) adrenaline in 1 ml aliquots around the 
bleeding points results in hemostasis in upto 100% of patients with bleeding 
peptic ulcers, probably by a combination of vascular tamponade and 
vasoconstriction, with a concomitant reduction in re-bleeding rates from 40% 
to 15%.68 The dose required  is variable but larger volumes (13-20ml vs. 5-
10ml) in high risk patients (Forrest type I or IIa lesions) results in less 
rebleeding (15.4% vs. 30.8%). Although injection with adrenaline is successful 
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in achieving initial hemostasis, 15-36% of patients were found to have 
rebleed.69 Sclerosants such as ethanol, polidocanol and ethanolamine are as 
effective as adrenaline but carry more risk.  
Thermal techniques 
Thermal hemostasis is achieved by compression of the artery during 
heating (coaption) and/or the effect of heat on tissue.   
          Non-contact thermal techniques currently available are Argon Plasma 
Coagulation (APC) and laser (Nd:YAG). APC involves conduction of a high 
frequency electrical current through a beam of ionized argon gas, resulting in 
superficial tissue damage and coagulation. A prospective observational study 
of APC in 254 patients with non-variceal UGIB revealed initial hemostasis 
rates of 75.9% and re-bleeding rates of 5.7%.16 Due to technical constraints of 
the technique, laser therapy is not routinely used in the management of non-
variceal UGIB. 
In contrast to APC and laser, Bipolar Electrocoagulation (BPE) and 
Heater Probe Thermocoagulation (HPT) use thermal contact to achieve 
haemostasis by compression of the vessel, Combination therapy with HPT 
and adrenaline in the treatment of actively bleeding peptic ulcers resulted in 
haemostasis in up to 98.6%, with re-bleeding in 8.2% 70 although added 
benefit is confined to high risk lesions. The risks associated with application of 
heat to bleeding lesions are due to the requirement for tissue contact, lack of 
control of depth of injury and difficulty in treating multiple or diffuse lesions. 
Mechanical hemostasis 
Mechanical hemostasis with endoloops or clips , has an increasing role 
in the control of non-variceal UGIB. Endoclips are deployed on a visible 
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vessel to achieve vascular compression and can achieve hemostasis in up to 
100% of cases. Comparative studies suggest lower rebleeding rates than 
adrenaline injection.71 Hemoclips can be technically difficult to apply if the 
ulcer is relatively inaccessible, for instance high on the gastric lesser curve or 
on the posterior duodenal wall.  
Endoscopic band ligation (EBL) is currently technically easier to use 
than endoclips and has been shown to be safe and effective for control of 
small lesions in a small series of acute peptic ulcer bleeding 72 and with 
bleeding due to Dieulafoy’s lesions. Newer techniques under evaluation 
include endoscopic suturing and cryotherapy .73 
Vreeburg et al. in their series, noted endoscopic intervention rates of 
21% , with injection therapy being instituted in as many as 74% with bleeding 
peptic ulcers. 
 “SECOND-LOOK” ENDOSCOPY AND ENDOSCOPIC RE-TREATMENT 
Routine “second look” endoscopy, in the absence of established 
rebleeding or patient instability, has gone out of vogue after studies showed 
no benefit with regard to clinically significant outcomes for unselected patient 
populations, although there may be a role in high risk patients. Repeat 
therapeutic endoscopy may be indicated (depending on local endoscopic and 
surgical expertise) if there is clinical evidence of re-bleeding74 or if the initial 
therapeutic procedure was unsuccessful or partially successful.  
Surgical therapy in non variceal bleed  
Pharmacologic and endoscopic approaches have progressively 
curtailed the use of operative therapy for PUD. Elective surgery is now rarely 
indicated and emergency operations are much less common. Vagotomy and 
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drainage procedures are technically simple but are associated with higher 
ulcer recurrence rates. Vagotomy and resection approaches offer lower ulcer 
recurrences but are associated with considerable mortality and morbidity.75, 76 
Gastric devascularisation has been tried as a salvage procedure for 
hemorrhagic gastritis. 
ACUTE VARICEAL UPPER GI BLEED1 
Resuscitation 
A patient with variceal hemorrhage requires immediate stabilization. 
During resuscitation, coagulopathy should be corrected with fresh frozen 
plasma, vitamin K and platelet transfusions, if required.  
Pharmacotherapy 
Pharmacologic efforts to treat variceal bleeding have focused on 
diminishing portal blood pressure by shunting blood away from the mesentery 
through the use of smooth muscle constrictors. Vasopressin causes 
splanchnic vasoconstriction and intravenous infusion causes decreased portal 
blood pressure with an increase in systemic arterial pressure and a decrease 
in heart rate. Terlipressin is a long-acting analogue of vasopressin that also 
reduces portal blood flow through splanchnic vasoconstriction. It has a slightly 
better safety profile and can be dosed at 4–6-hour intervals rather than by 
continuous infusion. For both agents, because the vasoconstriction is 
nonspecific, mesenteric or cardiac ischemia can occur. 
Nitrate preparations 
By causing venodilation, nitrates reduce systemic blood pressure and 
mildly decrease portal blood pressure. In studies that combined nitrates with 
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vasopressin, bleeding control was improved and toxicity was less compared 
with vasopressin alone. 77 
 Somatostatin and analogues 
The synthetic analogue of somatostatin, octreotide is thought to have 
three principal mechanisms in variceal bleeding. It blocks the increase in 
hepatic venous pressure, causes splanchnic vasoconstriction and 
downregulates enteric secretion and motility. Its low toxicity profile has made 
it a popular empiric choice for suspected portal hypertensive bleeding. In trials 
of acute variceal bleeding, it was more or at least as effective as vasopressin 
but with fewer adverse effects.78 
 
Endoscopic Therapy 
It should be performed in an intensive care unit after adequate volume 
resuscitation. Endotracheal intubation with mechanical ventilation should be 
considered in any patient with active hematemesis or a decreased level of 
consciousness in order to protect the airway and to minimize the chance of 
aspiration. 
The mainstay of endoscopic therapy for bleeding oesophageal varices  
is injectable vascular sclerosants. There are several types of sclerosants 
including morrhuate, tetradecyl sulfate and ethanolamine. They can be 
injected intravariceally or paravariceally. 
          Endoscopic sclerotherapy (EST) produces hemostasis by injuring 
endothelium and provoking variceal thrombosis and through a pressure effect 
from thrombus formation in an adjacent blood vessel.79 Total obliteration of 
varices usually requires multiple endoscopic sessions. Sclerotherapy can be 
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complicated by chest pain, fever, pleural effusion and dysphagia. Esophageal 
ulceration with late stricture formation, perforation and bacteremia are other 
possible sequelae.  
More recently, endoscopic variceal ligation (EVL) has emerged as an 
effective treatment for esophageal varices. Using a transparent cylinder 
attached to the end of the endoscope, a varix is suctioned into the cylinder, 
and a rubber band is deployed around the varix, causing hemostasis, 
thrombosis, and sloughing of the variceal column. EVL may be technically 
more difficult in an actively bleeding patient because visualization of the varix 
is recommended before suction is applied. 
In a comparison of EVL and sclerotherapy for treatment of active 
bleeding in cirrhotic patients, EVL was more successful for control of spurting 
varices. Bleeding ceased for at least 3 days in 97% of the EVL patients but in 
only 76% of the sclerotherapy patients. In the same study, EVL patients also 
required fewer blood transfusions and had fewer complications (5% vs. 29%) 
and lower mortality than patients treated with sclerotherapy.80 In a recent 
randomized controlled trial, EVL alone was compared with EVL and adjuvant 
sclerotherapy of varices that were too small to be eradicated by banding. 
Although complication rates and recurrent bleeding rates were similar 
between the two groups, the patients who received adjuvant sclerotherapy 
had a significantly lower rate of variceal recurrence. At 1 year, the likelihood of 
variceal recurrence was 45% among patients who received only EVL as 
compared to 24% for those who also received sclerotherapy.81  
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These studies suggest that optimal results may be seen from a 
combination of endoscopic therapies to control bleeding and sequentially 
eradicate varices to prevent rebleeding. 
When esophageal varices show endoscopic stigmata of recent 
hemorrhage or when there is a high clinical suspicion that variceal bleeding is 
responsible for the patient’s hemorrhage, endoscopic variceal ligation should 
be performed at 1–2 week intervals until the varices are obliterated. Follow-up 
endoscopy would be performed every 3–6 months thereafter to rule out 
variceal recurrence. 
EVL has replaced sclerotherapy as the standard endoscopic treatment 
to prevent rebleeding because EVL obliterates varices in fewer treatment 
sessions with a lower rate of rebleeding and lower mortality.82 A Japanese 
study that compared EVL with sclerotherapy for treatment of variceal bleeding 
in 101 patients found that hemostasis could be achieved in all patients of both 
treatment groups and that obliteration was approximately 90% in both groups. 
However, the rate of rebleeding was 40% in the sclerotherapy group and only 
29% in the EVL patients. 
                 On an average, EVL treatments were completed in 2.1 sessions 
versus 3.7 sessions for sclerotherapy. The most common complications, 
rebleeding and intramural hematomas, were seen less frequently in patients 
who received EVL.83 
Active bleeding from gastric varices or portal hypertensive gastropathy 
may be  difficult to treat endoscopically, though heater or bipolar probe and 
argon plasma coagulation have been tried in acute bleeding from portal  
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hypertensive gastropathy  and sclerosant and glue injection as well as 
banding have been tried for gastric varices. 
Surgical and Angiographic Shunts 
When portal hypertensive bleeding (oesophageal or gastric varices or 
portal hypertensive gastropathy) cannot be controlled with medical or 
endoscopic therapy, surgical shunts and angiographic portosystemic shunts 
(Transjugular Intrahepatic Portosystemic Shunting) should be considered. 
There are several surgical shunt options: portocaval, mesocaval, and 
splenorenal shunts. An additional surgical option to control variceal 
hemorrhage is oesophageal transection.  
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                                                     CHAPTER 4 
MATERIALS AND METHODS 
   
Four hundred and six consecutive patients with Upper GI bleed, 
referred for upper GI endoscopy to the endoscopic unit of Govt. General 
Hospital, Chennai were included in the study. 
Design of the study - Prospective cross sectional study  
Period of study  -          One year   
Ethical clearance -          Obtained  
Consent                   -          Informed consent from all the patients 
 
Patient selection 
Inclusion criteria 
Patients with upper GI bleed (hematemesis, melena or hematochezia 
with bloody nasogastric aspirate) 
 The patients who fulfilled the above mentioned criteria and did not have any 
contraindications for endoscopy and were willing for undergoing upper GI 
endoscopy were enrolled in the study. 
Exclusion criteria 
1. Comatose patients 
2. Patients with stage 3 and 4 Hepatic encephalopathy 
3. Myocardial infarction 
4. Perforated viscus 
5. Lack of willingness to undergo UGI endoscopy  
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Protocol 
1. All patients who met the above criteria were included in the study  
The following were noted in each patient 
1. Age 
2. Gender   
3. Presentation- hematemesis, melena, hematochezia 
4. Severity of bleed-minor, moderate or massive 
• Minor bleed-no hemodynamic instability, <10% blood loss 
• Moderate bleed - postural  hypotension and orthostatic 
tachycardia, 10-20% intravascular volume  loss 
• Massive bleed-shock (resting hypotension) - 20-25% 
intravascular volume loss 
5. Associated factors-Alcohol use, smoking, use of non-steroidal anti-
inflammatory drugs (NSAID), corrosive ingestion and past history of 
upper GI bleed  
6. Comorbid conditions –Ischemic heart disease, congestive cardiac 
failure, renal failure, liver disease, disseminated malignancy 
7. Physical examination and documentation of tachycardia and 
hypotension and the clinical diagnosis 
 8. Requirement for blood transfusion 
Endoscopy 
Upper GI endoscopy was performed in all patients, findings documented and 
requirement and mode of endoscopic therapy to control bleeding in indicated 
cases, noted. 
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Early endoscopy was defined as  endoscopy performed within 24 hours of  
seeking medical care. 
Peptic ulcers were classified based on the Forrest classification and  
varices by the classification proposed by Sarin et al. The grading of 
oesophageal varices was taken as follows: small and straight (grade I); 
tortuous and occupying less than one third of the esophageal lumen (grade 
II); or large and occupying more than one third of the esophageal lumen 
(grade III). 
Rockall score was calculated in all patients based on the following criteria 
• Age 
• Shock (assessed from pulse rate and blood pressure) 
• Comorbid conditions (cardiac, renal, liver, others) 
• Endoscopic stigmata of recent bleed  
• Endoscopic diagnosis 
On summing up different levels of a point grading system, scores 
ranging from 0 to 11 were obtained.  
Rebleed was  defined as fresh hematemesis or melena associated with 
the development of shock or a fall in hemoglobin concentration of at least 2 
g/dl in 2 hours. 
The rebleed, requirement of blood transfusions and mortality were 
documented and the efficacy of Rockall score as a predictor of rebleed was   
analyzed.  
The concordance between the initial clinical diagnosis and endoscopic 
findings were recorded.  
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Statistical analysis -Student’s t test, Chi-square tests and Fisher’s exact 
test as appropriate were used for comparison between groups. A P value 
of 0.05 or less was regarded as significant. 
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 CHAPTER 5 
RESULTS 
 
A total number of 406 patients were studied.(male-276 (68%),female-
130 (32%) with an range of 12 – 84 years (Mean 40.8 years , SD-16.3 years). 
The cases comprised 0.53% of the hospital admissions and 13.4% of 
upper GI endoscopies performed during the time duration of study.  
Table 5.Age Distribution 
  
 
Fig 2.Age distribution 
0
20
40
60
80
100
120
No.of patients
<20 20-39 40-59 60-79 >80
Age
AGE DISTRIBUTION
Male
Female
 
Age group Male Female No. of cases 
<20 15 22 37 
20-39 107 47 154 
40-59 106 41 147 
60-79 45 20 65 
>80 3 0 3 
Total 276(68%) 130(32%) 406 
 
 
li
Most of the patients- 107 (25.8%) were observed to fall into the 20-39 years 
age group 
Presentation 
The majority of patients presented as hematemesis. 
Table 6.Mode of presentation 
Age Hematemesis Melena H+M Hematochezia Total 
<20 28 3 6  37 
20-39 94 15 43 2 154 
40-59 73 26 47 1 147 
60-79 36 8 21 0 65 
>80 3 0 0 0 3 
total 234 52 117 3 406 
 
Severity of bleed 
The majority of patients presented with moderate bleed, and only 
18(4.4%) presented with massive bleed.  
Table 7. Severity of bleed 
Age Minor Moderate Massive Total 
<20 25 10 2 37 
20-39 74 74 6 154 
40-59 59 81 7 147 
60-79 29 33 3 65 
>80 0 3 0 3 
Total 187 201 18 406 
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Associated factors 
Table 8. Associated factors 
Age 
 
Alcohol 
 
Smoking 
 
NSAID 
 
Corrosive 
 
Past bleed 
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Alcohol, smoking and NSAID use were found to be the major associated 
factors. 
The major comorbidities included cardiac problems including ischemic 
heart disease and congestive cardiac failure in 18 patients,renal failure in 4 
patients and liver disease in 70 patients. Other comorbidities included COPD, 
diabetes mellitus and systemic hypertension.  
Timing of Upper GI endoscopy 
228 cases (56.2%) were subjected to Upper GI endoscopy to ascertain 
causes of bleed within 24 hours(early) and 178(43.1%) cases after 24 hours 
(late) 
Fig 5. Timing of upper GI endoscopy 
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Endoscopic findings 
Non variceal causes predominated and were the most common 
sources of bleed in all age categories. The upper GI endoscopy was non 
contributory to a diagnosis in 37 cases.  
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Table 9. Cause of bleed 
Varices Non Variceal 
91(22.4%) 315(77.6%) 
 
Fig 6.Cause of bleed 
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 Causes of bleed- age distribution 
Table 10.Causes of bleed- age distribution 
Age Varices Nonvariceal Total 
<20 12 25 37 
20-39 31 123 154 
40-59 38 109 147 
60-79 10 55 65 
>80 0 3 3 
Total  91 315 406 
 
Nonvariceal causes of UGI bleed  predominated in all age groups. 
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Fig 7. Cause of bleed- age distribution 
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Nonvariceal causes 
Table 11.Nonvariceal causes 
Age  
Duodenal 
ulcer Gastric ulcer MW tear Gastritis Duodenitis Esophagitis Malignancy 
Angiodyspla
sia 
<20 4 2 0 13 11 5 1 1 
20-39 23 5 1 69 38 29 2 3 
40-59 16 16 0 62 41 24 8 1 
60-79 8 5 1 29 16 11 5 0 
>80 1 0 0 1 1 2 0 0 
Total 52 28 2 174 107 71 16 5 
 
Since some subjects had more than one lesion, (eg. duodenal ulcer 
with gastritis), the sum total of all lesions in the nonvariceal category 
exceeded the total number of patients (315) with nonvariceal bleed. 
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Variceal causes 
Table 12. Variceal causes 
Age  Oeso Varices   GOV1 GOV2   IGV1     IGV2       Varices 
<20 5 1 3 3 0 12 
20-39 16 5 9 1 0 31 
40-59 21 4 11 2 0 38 
60-79 2 2 6 0 0 10 
>80 0 0 0 0 0 0 
Total 44 12 29 6 0 91 
 
Portal hypertensive gastropathy and duodenopathy were found in 72 and 15 
subjects. 
Fig8.Diagnosis
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Endoscopy and clinical diagnosis 
Endoscopic findings were more in concordance with clinical diagnosis 
in MW tear (90%), duodenal ucer (88%), varices (84%) and gastritis (80%) 
compared to malignancy (60%) and gastric ulcer(52%) 
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ENDOTHERAPY 
 Varices 
Table 13.Grading of varices and endotherapy 
Varices Number of cases Endotherapy done 
Grade I   8      - 
Grade 2 31    30 
Grade 3  46    45 
IGV   6      - 
Total 91    75 
 
Peptic ulcers 
Table 14.Forrest classification and endotherapy 
Forrest class Number of cases Endotherapy 
              IB 12  11 
             IIA 16  15 
             IIB 15  14 
             IIC 13   - 
             III 24   - 
          Total  80 40 
 
The peptic ulcers that were found to have an active ooze, visible vessel 
or adherent clot (Forrest class IB, IIA, IIB), were subjected to endotherapy. 
 Of the 171 cases with varices and peptic ulcers, endotherapy was 
done in 115 (50% of peptic ulcers and 82.4% of variceal bleed) cases. 
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Adrenaline injection was performed in 40 cases; endoscopic sclerotherapy 
was done in 40 cases and endoscopic variceal ligation in 35 cases 
Fig 9. Forrest classification of peptic ulcers 
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Rockall score 
 The mean Rockall score was calculated in all patients based on the 
age, hemodynamic status, comorbidity, endoscopic diagnosis and SRH. The 
mean Rockall score was 3.3(S.D 1.7, range  0 – 10) 
Table 15.Rockall Score- distribution   
Score No. Of Patients 
0 21 
1 78 
2 76 
3 58 
4 50 
5 70 
6 15 
7 25 
8 11 
9 1 
10 1 
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The patients were classified into three risk groups, based on the 
Rockall score. Those with a score less than 3, into group A (low risk), score of 
3-5 into group B (moderate risk) and those with a score of 6 or more into 
group C (high risk). Most patients were observed to belong to the first two 
groups. The mean Rockall score in the low risk group was 1.3, that of the 
moderate risk group was 4.1 and that of the high risk group was 7. 
The distribution of cases in all the three groups with respect to mean age, 
gender, comorbidity, hemodynamic status and the endoscopic diagnosis, was 
recorded.  
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Rockall Score- risk groups 
Table 16.Risk groups- age distribution  
Age Low risk(A) Mod risk(B) High risk(C) Total 
<20 20 16 1 37 
20-39 79 59 16 154 
40-59 62 62 23 147 
60-79 14 40 11 65 
>80 0 1 2 3 
Total 175 178 53 406 
  
In the the high risk group, the number of patients aged 60 years or 
more was not found to be statistically higher(P=0.11) 
Table 17. Risk groups- variables 
Variable Low Risk(A) Mod Risk(B) High Risk(C) 
N 175 178 53 
Mean Age 36.5 43 47 
Male 113 122 41 
Comorbidity 5 91 45 
Tachycardia 68 148 53 
Hypotension 0 82 45 
No Lesion 36 1 0 
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Fig .11.Rockall Score- risk groups 
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Rockall Score and cause of bleed 
Variceal bleed was observed in a higher proportion in the moderate 
and high risk groups. 
Table 18.Risk groups- cause of bleed  
Cause  Low Moderate High 
Varices 6 52 32 
Nonvariceal 169 126 21 
In the high risk group, the  number of  bleeds due to variceal causes 
were significantly higher as compared to the low risk group.(P value<0.001) 
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Fig 12.Risk groups- cause of bleed 
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Rockall Score and outcome 
The need for packed red cell transfusion and the number of patients 
who had rebleed were noted, along with  mortality. 
Table 19.Rockall Score and outcome 
Variable Low Risk Mod Risk High Risk         Total  
PRBC  8 72 41 121 
Rebleed 4 28 32 64 
Mortality 0 0 3 3 
   
The requirement of blood transfusion and the incidence of rebleed  was  
higher with moderate and high risk groups. 
Table 20.Risk groups and outcome- comparison 
    Low vs. mod risk 
         P value 
Low vs. High risk  
   P value 
PRBC transfusion reqt <0.001 <0.001 
Rebleed <0.001 <0.001 
Mortality 1 0.01 
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The requirement of blood transfusion was significantly higher in the 
moderate and high  risk groups as compared to the low risk groups, (both P 
values less than 0.001) , as was the incidence of rebleed which was more in 
the moderate and high risk groups as against the low risk group.( P<0.001 in 
both) 
There was no mortality in the moderate and low risk groups. There 
were 3 deaths in the third group which was statistically significant as 
compared to the low risk group and moderate risk group. (P value =0.01) 
         It was noted that in  the 64 cases who had rebleed, 44(68.8%)had 
nonvariceal causes [ peptic ulcer- 21(Forrest IB(6), IIA(7), IIB(8)), 
gastroduodenitis-18, oesophagitis- 3, gastric malignancy-2 ]and the rest were 
variceal (grade III varices-12, grade II varices-8) .The rebleed was not found 
to be significantly higher for variceal causes ( P value = 0.7), though a higher  
proportion of varices were found to have a rebleed.. 
 Of the patients who had rebleed, 9 had received prior EST and 7 had 
received EVL . In peptic ulcers with rebleed, 18 of the 21 cases with rebleed 
had received prior injection therapy with adrenaline (Forrest IB-5, IIA-6,IIB-7). 
Following the rebleed, 11 patients with varices were given EST and 9 patients 
were subjected to band ligation of varices. Adrenaline was injected locally to 
control rebleed in all the   rebleeding peptic ulcers.  
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CHAPTER 6 
                                                 DISCUSSION 
The clinical and endoscopic profile of the four hundred and six patients 
presenting to the endoscopy unit of the institution were analysed. Age, 
gender, severity of bleed, mode of presentation, etiology and associated 
factors were documented, along with the documentation of Rockall score, 
requirement of blood transfusions, rebleed and endotherapy instituted. 
The Rockall score has been validated by several studies, for predicting 
rebleed and mortality. In this study, along with the determination of the 
Rockall score, the subjects were divided into three risk groups. The available 
data is compared with contemporary literature and utility of Rockall score in 
risk stratification, is evaluated.  
Age distribution 
The mean age was 40.8 years (S.D 16.3 years) with an age range of 
12-84 years. It was lower than that observed in the RUGBE (Canadian 
Registry on Upper Gastrointestinal Bleeding and Endoscopy Database of 
1869 patients) study by Barkun et al.11, Rockall and Logan8  et al. and 
Yavorski et al.9 
Table 21.Age distribution- comparison 
 Barkun et al11 Rockall et al8 Yavorski et al9 Present 
study 
Mean age 66 66 52.06 40.8 
 Age Range 7-105 16-103 1-99 12-84 
Total 
number 
1869 2332 3294 406 
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 The majority of patients in the present study fell into the age group of 
20-39 years -157(38.7%).  Only 3 subjects (0.7%) were above 80 years, as 
compared to 634 (27.2%) noted by Rockall et al, who concluded that the 
incidence of bleed significantly increased with age. 
Longstreth and colleagues, in their series, noted that 47% of their 
patients were above 60 years of age, as compared to the present study where 
it was noted to be only 9.9%. 
Gender distribution 
Male predilection (68%) was noted in this study, in concordance with 
the RUGBE database, where 62% were males and that noted by Rockall et al. 
(57% males). Longstreth et al also had noted a male predilection of 67.9%. 
Presentation 
 
Majority of patients patients-351(86.5%)  had  hematemesis  as a 
presenting feature and 169(41.6%) had melena, as compared to RUGBE 
data11 where  hematemesis was noted in 58% of patients and melena in 69%, 
and that observed by Longstreth et al 10 who noted that 33% of their  patients 
had hematemesis and 81% had melena. 
Hematochezia was noted in 3(0.7%), which was much lower than that 
noted by Barkun et al(15%) and  Laine et al (5%).13 
 
 Associated factors 
Longstreth et al noted history of NSAID use in 53% and alcohol use in 3% of 
patients in their series. The present study noted a much higher percentage of  
patients with alcohol use- 91(22.4%) , though NSAID use was  noted only in 
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76(18.7%) of patients. RUGBE data showed a previous documented UGIB in 
19.5% of patients, whereas in the present study, it was noted to be 6.4%.  
Timing of endoscopy 
 Chak et al observed that early endoscopy was done in 82% of their 
patients. 
 Rockall et al noted that 1108(50.1%) patients underwent early 
endoscopy which was comparable to that noted in the present study-
228(56.2%).  
Causes of Upper GI bleed 
Barkun et al 11 noted in the RUGBE study, that 56% had peptic ulcer 
disease as the primary etiology for UGI bleeding, followed by esophagitis 
(8.4%), Mallory Weiss tears (4.4%) and Dieulafoy lesions (2.5%).  
In the present study, 315 patients had non variceal causes of bleed,of 
which peptic ulcers accounted for 80(25.4%). 52(65%) were duodenal ulcers 
and 28(35%) were gastric ulcers. Gastritis-174(55.2%)and duodenitis-
107(34.8%) accounted for the majority, with oesophagitis seen in 71(22.5%), 
much higher than that noted by Barkun et al. Mallory Weiss tears accounted 
for  2(0.6%) cases.  
Rockall and Logan studied 2332 cases of UGIB, taking into 
consideration both variceal and non variceal etiology of bleed. Vreeburg et 
al.84 studied 477 subjects presenting with Upper GI bleed in the Amsterdam 
area. The various causes, documented by them, in comparison to the present 
study is as follows: 
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Table 22.Causes of bleed- comparison 
 
 
Rockall et al 
n=2332 
Vreeburg  etal 
n=1389 
Present study 
n=406 
Peptic ulcer 842(36.1% ) 477(34.3%) 80(25.4%) 
Malignancy 93(4%) 30(2%) 16(3.9%) 
Mallory-Weiss tear 119(5.1%) 56(4%) 2(0.6%) 
Oesophagitis 241(10.3%) 155(11%) 71(22.5%) 
 Gastritis/erosions 240(10.3%) 118(8%) 174(55.2%) 
Varices 108(4.6%) 127(9%) 91(22.4%) 
A very high percentage of patients(55.2%) were noted to have gastritis, 
in the present study, as compared to that noted by Rockall et al. and Vreeburg 
et al. Varices were observed  in a much lower percentage  by Rockall et al. 
and Vreeburg (4.6% and 9% respectively), in comparison with this study 
(22.4%). 
In the present study, nonvariceal causes predominated in  all age 
groups , but it was not found to be significantly higher in patients aged >60 
years , as compared to those less than 60 years.( P value of 0.11)  
Peptic ulcer 
Table 23.Distribution of peptic ulcers 
Forrest  classification Laine et al13(%) Present study(%) 
I 18 15 
IIA 17 20 
IIB 17 18.8 
IIC 20 16.3 
III 42   30 
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      In the present study, the percentage of ulcers, belonging to various 
classes of the Forrest classification, were comparable to that noted by Laine 
et al13.The percentage of Forrest  class III ulcers(30%) were lower than that 
noted by Laine et al.  
Variceal hemorrhage 
  Sarin et al 85 noted that GOV1 constituted the majority( 74%)of gastric 
varices, followed by GOV2(16%), IGV1(8%) and IGV2(2%). Patients with 
gastric varices constituted 47(51.6%) of cases in the present study, of which 
GOV1 accounted for 25.5%, GOV2 formed the bulk with 61.7%, and IGV1 
accounted for 12.7%. There were no cases of IGV2. 
Endotherapy  
Endotherapy was done in 115 cases (28.5%) in the present study. 
Adrenaline injection was performed in 40 cases (50% of peptic ulcers), 
Endoscopic sclerotherapy was done in 40 cases and endoscopic variceal 
ligation in  35 cases (82.4% of variceal bleed). 
Vreeburg et al84. in their series, noted lower  endoscopic intervention 
rates, with 21% of patients with UGIB in their case series undergoing 
endotherapy. Injection therapy was  instituted in  74% of subjects with 
bleeding peptic ulcers which was higher when compared to 50% in the 
present study.  
Rockall Score 
The mean Rockall score was 4.8 (SD : 1.9, range: 0 -10) in the RUGBE 
study whereas in the present study, it was lower( mean score : 3.3, S.D:1.7, 
range: 0-10 ) indicating that most patients belonged to the low risk category.  
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Table 24.Risk groups based on Rockall Score 
RISK RUGBE Rockall et al. Present study 
Low 240(13%) 1058(45.4%) 175(43.1%) 
Moderate 999(53%) 1181(50.7%) 178(43.9%) 
High 630(34%) 93(3.9%) 53(13%) 
Total 1869 2332 406 
  
As compared to the RUGBE study11 where the majority belonged to the 
moderate and high risk group, in the present study, most of the patients had a 
low Rockall score(less than 3) and belonged to the low risk group. However, 
the percentage of patients belonging to the high risk group, in the present 
study, was higher than that noted by Rockall et al(13% vs. 3.9%)  
Table 25. Comorbidity and hemodyamic instability 
 Rockall et al Present study 
Comorbidity  1378(59.1%) 141(34.7%) 
Hypotension  256(11.2%) 127(31.2%) 
 
The comorbidities were lower in the present study (34.7%) as 
compared to that noted by Rockall et al ( 59.1%),and Yavorski et al( 50.9%).9  
but hemodynamic instability was higher (31.2%) than that noted by Rockall et 
al( 11.2%). 
Adverse outcome 
In the present  study, the requirement of blood transfusion was 
significantly higher in the moderate and high  risk groups as compared to the 
low risk groups, (both P values less than 0.001) , as was the incidence of 
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rebleed which was more in the moderate and high risk groups as against the 
low risk group( p<0.001 in both). These findings are compared to that 
observed by Patel et al. 
Table 26.Adverse outcomes-comparison 
 Patel et al Present study 
 Low Mod high low Mod high 
PRBC 
reqt 
44% 56% 76% 4.6% 40.4% 77.3% 
Rebleed 6% 21% 24% 2.3% 15.7% 60.3% 
 
In comparison with the observations of Patel et al, the need for packed 
red cell transfusions were less in all groups in the present study. But, the 
percentage of rebleed , was higher than that noted by Patel et al, as far as the 
high risk groups were concerned.  
Akash et al56, in their study of upper GI bleed, from a tertiary care 
institution at Chennai,also noted that Rockall score correlated well with the 
need for blood transfusions, rebleeding and mortality. Of the 100 patients with 
nonvariceal upper GI  bleed  studied by them,30 patients had a  Rockall score 
of  1-3 and 28(94%)had no rebleed and did not require transfusions. 28(28%) 
patients had a clnical score of 4-6, out of which 6(21.4%)had rebleed and 1 
patient expired. Of the 20 patients with Rockall score 7-11, 4(20%) patients 
had rebleed and 7( 35%) died and the remaining had prolonged hospital stay.  
In the present study, the rebleed rate in moderate risk group was 15.6% and 
slightly lower than  that noted by Akash et  al.(21.4%)  but the rate of rebleed 
in the  high risk group was higher.  
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The following table gives a comparison of the rebleed noted in the 
RUGBE11 study and present study. 
Table 27.Risk groups and rebleed- comparison 
RISK RUGBE Present study 
Low  21 (8.8%) 4(2.3%) 
Moderate   130(13%) 28(15.7%) 
High  107(17%) 32(60.4%) 
Total  258 64 
 
The rebleed rates in the present study(15.8%)  was comparable to that 
observed by Barkun et al.11 viz.13.8% and Rockall et al.(15.4%) but higher 
than that noted by Yavorski et al(7.1%). 
        It was noted that  in the low risk group, the rebleed was lower in the 
present study (2.3%) as compared to RUGBE data, where 8.8% rebled and 
that noted by Rockall et al. 41 where 4.3% had rebleed. But, it was observed 
that in the high risk group, 60.4% of patients had rebleed which was higher 
than the rate of 17% noted in the RUGBE data. 
Limitations of the study 
1. As the study centre is a tertiary care institution, referral bias might have 
occurred, with a higher number of patients with UGIB falling into 
moderate and high risk groups, which might not be a true reflection of 
the scenario in the general population. 
2. The average length of hospital stay was not documented in the 
subjects, as was the need for emergency surgery. Thus, the usefulness 
of Rockall score in validating the above parameters could not be 
ascertained.                                                                                     
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CHAPTER 7 
                                                   CONCLUSION 
 
• Upper GI bleed is an important indication for endoscopic referral to this 
institution  
• The majority of patients were noted to be less than 60 years of age, 
with a male predilection. 
• Most cases presented with minor or moderate upper GI bleed, with 
massive bleeds constituting a minority. 
• NSAID and alcohol use as well as smoking were notable associated 
factors. 
• Nonvariceal bleed predominated in all age groups, with peptic ulcers 
and gastroduodenal erosions accounting for the majority of cases. 
• Good clinicoendoscopic correlation in varices, MW tears, and duodenal 
ulcer compared to gastric ulcer and malignancy. 
•  Based on the Rockall score,most of the cases fell into the low and 
moderate risk groups( score<6). In the high risk group, the number of 
patients with variceal bleed were significantly higher compared to the 
low risk group. 
• The rebleed was not significantly higher in patients with varices, as 
compared to nonvariceal causes. 
• The requirement of packed red cell transfusion and rebleed were 
higher in patients with higher Rockall score (moderate and high risk 
groups). The mortality was significantly higher in the high risk group as 
compared to the low risk group. Hence, Rockall score has been found 
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to correlate well with clinical outcome, including need for transfusions, 
rebleeding and mortality, and may be used for effective triage of 
patients into outpatient and inpatient care, as well as to predict 
prognosis in upper GI bleed.  
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CHAPTER 8 
SUMMARY 
Upper GI bleed is one of the most common gastrointestinal 
emergencies, with considerable morbidity and requires significant hospital 
resource utilization. The modes of presentation, etiology and clinical spectrum 
may vary and an interplay of various causative and associated factors have 
been observed.  
                    Early upper GI endoscopy is of paramount importance in the 
diagnosis as well as treatment and has also been used to stratify risk in upper 
GI bleed. Of the various risk stratification scores used, Rockall score is a 
simple and useful score , based on clinical and endoscopic criteria and has 
been shown to represent an accurate and valid predictor of rebleeding, 
mortality and morbidity in the form of blood transfusions and prolonged 
hospital stay. Thus, it can be used in the triage of patients, to either outpatient 
care (low risk) or admission and intensive care (moderate or high risk), with 
anticipation of morbidity and rebleed.  
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Plate 1. Forrest Class IIB: Ulcer with adherent clot 
 
 
 
 
Plate 21. Forrest Class IIC: Ulcer with pigmented spot 
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Plate 2 Forrest class III.: ulcer with clean base 
 
 
 
 
Plate 3. Esophageal varices 
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 APPENDIX 
UPPER GASTROINTESTINAL BLEED- CAUSES, ENDOSCOPIC PROFILE 
AND USEFULNESS OF ROCKALL SCORE 
PROFORMA 
SL. No  
Name  
IP Number  
GE number  
Address  
 
 
 
Age  
Sex  
Date of Admission  
Presentation Hematemesis/Melena/Hematochezia 
Severity of bleed Minor/Moderate/Massive 
Associated .factors 
Alcohol 
Smoking 
Corrosive ingestion 
NSAID 
Past GI bleed 
 
 
Comorbid conditions 
IHD 
CCF 
Renal failure 
Disseminated malignancy 
 
 
Examination 
Pulse 
Blood pressure 
Pallor 
Abdomen : 
 
Clinical diagnosis  
Timing of endoscopy  
UGI Endoscopy  
Endoscopic findings  
FORREST class( as applicable)  
SARIN classification  
Grading of varices  
 Endoscopic diagnosis  
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Variceal/nonvariceal  
ROCKALL SCORE-COMPONENTS  
AGE  
SHOCK  
COMORBIDITY  
ENDOSCOPIC DIAGNOSIS  
ENDOSCOPIC SRH  
TOTAL Score  
RISK GROUP A/B/C 
ENDOTHERAPY  yes/no 
Details of endotherapy Adrenaline/EST/EVL 
PRBC transfusion  
Rebleed Yes/No 
Endotherapy for rebleed Adrenaline/EST/EVL 
Death  
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1 775403 5331/05 Velu m H,M MD A E G,D NV 0 1 0 0 1 2 A
2 775414 5333/05 Mani m H MD E G,D NV 0 1 0 0 1 2 A
3 779361 5330/05 Govindasami m H MN N, A E G,D,GU 1B NV 0 0 0 0 1 1 A A Y A
4 779020 5327/05 Poongavanam m m MD A,S O E V GOV1 3 V 0 1 2 0 1 4 B B EVL
5 775686 003/06 Mahendra m H MN E V OV 1 V 0 0 0 0 1 1 A
6 774328 002/06 Shakila f H MN C E G NV 0 0 2 0 1 3 B
7 776294 008/06 Dhanapal m H,M MN E G,D NV 0 0 0 0 1 1 A
8 777554 134/06 Shanthi f H,M MS S E V,PHTG GOV1 3 V 0 2 2 2 1 7 C B EVL Y EVL
9 776788 34/06 Prabhu m H MN E G NV 0 0 0 0 1 1 A
10 776825 71/06 Mariyam f H MD A L G NV 0 1 0 0 1 2 A
11 776281 104/06 Nagalingam m H MD A,S L G,D NV 0 1 0 0 1 2 A
12 776627 97/06 Venkatesh m M MD A,S L E V,PHTG IGV1 V 0 2 2 2 1 7 C B
13 776289 76/06 Chinnakulandai m M MD L G,D NV 1 1 0 0 1 3 B
14 777346 126/06 Samuel m H MN E G,D NV 0 0 0 0 1 1 A
15 777372 128/06 Ellammal f H MN E O,G,D NV 1 0 0 0 1 2 A
16 777206 140/06 Elias m H MN C E O,G NV 0 0 0 0 1 1 A
17 777037 138/06 Siva m H MN A E G NV 0 0 0 0 1 1 A
18 777538 165/06 Zarina f H MD B L E V,PHTG,PHTD GOV1 3 V 0 2 3 2 1 8 C B EVL Y EVL D
19 777973 218/06 Nitha f H MN N, E G NV 1 0 0 0 1 2 A
20 777983 141/06 Selvaraj m H,M MD A,S L E V,PHTG,PHTD GOV1 3 V 0 2 2 0 1 5 B B EVL
21 778535 233/06 Rajamani m H,M MD A,S L E G,PHTG,PHTD GOV1 3 V 0 2 2 0 1 5 B B EVL
22 779176 275/06 Jemini m M MD A L L V,PHTG,PHTD GOV2 3 V 0 1 2 2 1 6 C V EVL Y EVL
23 779827 262/06 Annammal f H MN A,S E MW,O,G NV 1 0 0 0 1 2 A
24 779834 268/06 Kumar m H MN A L O,G NV 0 0 0 0 1 1 A
25 780317 358/06 Renuka f H MN E O NV 0 0 0 0 1 1 A
26 780125 345/06 Panneer m H,M MN A,S E O,D NV 0 0 0 0 1 1 A
27 780458 369/06 Murugan m H MN A,S L E V,PHTG,PHTD GOV2 3 V 0 1 2 0 1 4 B EVL
28 780130 360/06 Subramani m H,M MD A,S L E V,PHTG,PHTD OV 3 V 0 2 2 2 1 7 C B EST Y EST
29 780319 361/06 Muniappan m H MN A,S E O,G NV 0 0 0 0 1 1 A
30 779671 304/06 Parthasarathy m M MD B E V IGV1 V 0 1 0 0 1 2 A
31 780951 394/06 Jayanti f H MS E V IGV1 V 0 2 0 0 1 3 B B
32 781450 208/06 Varadarajan m H MN N O L G,D,GU 3 NV 0 0 2 0 1 3 B
33 781758 461/06 Muthalagan m H,M MD S E G,D NV 0 1 0 0 1 2 A
34 781836 492/06 Venugopal m H MN A,S L O,GU 2A NV 1 0 0 2 0 3 B A
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35 781697 464/06 Kamala f H MN A,S E N NV 0 0 0 0 1 1 A
36 782075 454/06 Srinivasan m H MN A E G,D NV 0 0 0 0 1 1 A
37 781801 461/06 Krishnaveni f H MD L E V,PHTG,PHTD IGV1 V 0 1 2 0 1 4 B
38 783063 607/06 Mani m H,M MN E D NV 0 0 0 0 1 1 A
39 782574 601/06 Ganesan m M MD E D NV 0 1 0 2 1 4 B Y
40 783192 599/06 Soundaraj m H MN E O,G,D NV 0 0 0 0 1 1 A
41 782189 546/06 Anita f H,M MD E V OV 3 V 0 2 0 2 1 5 B EST
42 783288 640/06 Suresh m H "MD" A , S L GU 3 NV 0 1 0 0 1 2 A
43 783214 5240/06 Subramani m H,M MD L V,PHTG,PHTD GOV2 3 V 1 1 0 0 1 3 A B EVL
44 783647 384/06 Munnabhai m M MD L E V,PHTG,PHTD GOV2 3 V 0 2 3 2 1 8 C B EVL
45 787871 616/06 Balan m H,M MN A E G NV 0 0 0 0 1 1 A
46 784113 680/06 Gnanasekar m H,bleeding pr MS N E G NV 0 2 0 2 1 5 B B Y
47 783706 654/06 Dillibabu m h,m MD A E O,G,D NV 0 1 0 0 1 2 A B
48 784334 662/06 Kuppan m h MN N O E GU 3 NV 0 0 2 0 1 3 B
49 784315 678/06 Anjalakshi f h MN O E G NV 1 0 2 0 1 4 B
50 785351 727/06 Akila f H MN E G NV 0 0 0 0 1 1 A
51 784238 792/06 Manivel m H,M MN L O,G,D NV 0 0 0 0 1 1 A
52 789124 795/06 Dawood m M MN E O,G,D NV 0 0 0 0 1 1 A
53 785843 693/06 Ramya f H MN A E G NV 0 0 0 0 0 0 A
54 785667 872/06 Patchaiappan m  H MD S L GJ,V GOV2 3 V 1 1 2 0 1 5 B B EVL
55 785063 843/06 Manickam m H MN E G,MW NV 0 0 0 0 1 1 A
56 779208 224/06 Rajendran m M MN E G,D 3 NV 0 0 0 0 1 1 A
57 786453 816/06 Moorty m H MN A,S E N NV 0 0 0 0 0 0 A
58 786703 871/06 Kanagavalli f H,M MD O E N NV 1 1 2 0 0 4 B
59 785865 801/06 Shanmugam m H MN E G NV 0 0 0 0 1 1 A
60 787312 942/06 Chandrasekar m H MS A L V,PHTG IGV1 V 0 2 2 2 1 7 C B
61 788204 975/06 Manohar m H MN E Varices- grade NV 0 0 0 0 1 1 A
62 788712 973/06 Sadayappan m H MN O E O,A NV 0 0 2 0 1 3 B
63 787170 423/06 Usman basha m H,M MD L O,D NV 0 1 0 2 1 4 B Y
64 789200 1112/06 Jagannathan m H,M MD A, S E G,D NV 0 1 0 0 1 2 A
65 787384 945/06 Arumugam m H MD N O E G NV 1 1 2 0 1 5 B Y
66 789884 1156/06 Saroja f H,M MN SU L D,DU 3 NV 0 0 0 0 1 1 A B
67 789888 1186/06 Sivajnanam m H MD N E N NV 0 0 0 0 0 0 A
68 790450 1248/06 John Baskar m H MN E N NV 0 0 0 0 0 0 A
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69 789019 1194/06 Abdul khader m H MN A O E G NV 1 0 2 0 1 4 B
70 790693 1243/06 Periyasamy m H,M MD E O,G,D NV 0 1 0 0 1 2 A
71 790989 1248/06 Govindasami m H,M MS C L G,D NV 1 2 2 0 1 6 C Y
72 790421 1216/06 Xavier m H,M MN E N NV 0 0 0 0 0 0 A
73 789331 1367//06 Shanmugam m H,M MD L E V,PHTG OV 2 V 0 2 2 0 1 5 B B EST
74 788576 1221/06 Ganesh m M MN R L G NV 0 0 3 0 1 4 B Y
75 791504 1315/06 Napolean m H MN O E N NV 0 0 2 0 0 2 A
76 791523 1314/06 Krishnaveni f H MN S E N NV 0 0 0 0 0 0 A
77 791482 1312/06 Murali m H,M MD B L L V,PHTG OV 2 V 0 2 3 2 1 8 C B EST Y EST
78 790946 1251/06 Lakshmiammal f M MN E N NV 1 0 0 0 1 A
79 790955 1256/06 Alamelu f H MN N C E N NV 0 0 2 0 0 2 A
80 791284 1292/06 Mary f H MN O E G  NV 0 0 2 0 1 3 B Y
81 791290 724/06 Nagaraj m H MN N E N NV 1 0 0 0 0 1 A
82 792124 1305/04 Kathiresan m H MD O E O NV 0 1 2 0 1 4 B
83 792700 1366/06 Krishnan m M MD L MS NV 1 2 0 2 2 7 C
84 792598 1389/06 Ushar sharif m H MD B L O NV 2 2 0 2 1 7 C Y
85 799092 1390/06 Elumalai m M MD A,S E O,G NV 0 1 0 2 1 4 B
86 791827 1765/05 Chakravarti m H MD A,S E V,PHTG OV 2 V 0 2 2 2 1 7 C B EST Y EST
87 792475 1385/06 Durai m H MD N E N NV 1 1 0 0 0 2 A
88 794132 1537/06 Rajendran m H MD L L V, GOV2 3 V 0 2 2 0 1 5 B B EVL
89 794289 1125/06 Viswanathan m H,M MD N L N NV 1 0 0 0 0 1 A B
90 792487 14/06 Muniandi m M MD O L O,MS NV 0 2 2 2 2 8 C B
91 794311 1573/06 Elumalai m H,M MD A,S L E V,PHTG OV 2 V 0 2 2 2 1 7 C B EST Y EST
92 795036 1551/06 Sundar raman m H MN E G NV 0 0 0 0 1 1 A
93 792664 1531/06 Samuel m H MN O.L L O,G,D NV 0 0 2 0 1 3 B Y
94 794293 1541/06 Solaiammal f M MD E O,G,D,GU 3 NV 0 1 0 0 1 2 A
95 799583 1581/06 Saroja f M MD C L G NV 0 1 2 0 1 4 B B Y
96 795626 1574/06 Abhirami f H MN O E N NV 0 0 2 0 0 2 A
97 795793 1646/06 Laxmi f H,bleeding pr MD L O,D NV 1 0 0 0 1 2 A
98 795948 1664/06 Munusamy m H MN N O E G,D NV 0 0 2 0 1 3 B Y
99 796636 1725/06 Saktivel m H,M MS A,S E O,G,D,DU 3 NV 0 2 0 2 1 5 B B
100 796430 1736/06 Nagaraj m H MN E G NV 0 0 0 0 1 1 A
101 796261 1695/06 Velu m bleeding pr MN E N NV 0 0 0 0 0 0 A
102 796981 1777/06 Deviraj m H,M MD N C,O E GU 2B NV 0 2 2 2 1 7 B B A Y A
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103 796635 1724/06 Adilaxmi m H MN N O E O NV 1 1 2 0 1 5 B
104 797208 1686/06 Jeeva f H MN E N NV 0 1 0 0 0 1 A
105 796672 1776/06 Jayapandian m M MD A,S L ,DU 3 NV 0 1 0 0 1 2 A
106 797313 1806/06 Jagan m H,M MD L L V,PHTG,PHTD GOV1 2 V 0 1 2 2 1 6 C B EVL
107 797743 1778/06 K+D192artikraja m H MN L O,D NV 0 1 0 0 1 2 A
108 798313 1868/06 Nayaki f M MD E GU 2A NV 0 1 0 0 1 2 A A Y A
109 798359 1843/06 Paulsingh m H MN A,S L G,D NV 0 0 0 0 1 1 A
110 798238 1838/06 Kasivisalakshi f M MD E V,PHTG,PHTD OV 2 V 0 2 2 0 1 5 B B EST
111 791299 1920/06 Gomati f H MN R L H,D NV 0 0 3 0 1 4 B
112 798808 1906/06 Chinnathai f H MN L N NV 0 0 0 0 0 0 A
113 799225 1904/06 Venkatesan m M MD N E G,GOO NV 1 1 0 0 1 3 B
114 799118 1962/06 Kannan m H MD L V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EVL
115 798628 1378/06 Kalpana f H MN B L E V OV 1 V 0 2 0 2 1 5 B B
116 799496 1916/06 Selvi f H MN E N NV 0 0 0 0 0 0 A
117 799401 1014/06 Vijayan m H MN S E N NV 0 0 0 0 0 0 A
118 799902 1897/06 Madarasi m H MN S L G,DU 2A NV 0 0 0 0 1 1 A A Y A
119 799742 1992/06 Santosh m H MD L N NV 0 1 0 2 1 4 B
120 799418 3824/05 Jayalakshmi f M MD E V OV 2 V 0 2 2 0 1 5 B B EST Y EST
121 800778 2102/06 Sukanya f H MN E O,G,D NV 0 0 0 0 1 1 A
122 800387 2106/06 Saravanan m H,M MD S L G,D,GU 2A NV 0 1 0 0 1 2 A A Y A
123 769842 2069/06 Manimegalai f H,M MD E O NV 0 1 0 0 1 2 A
124 800979 2003/06 Palani m H,M MD A,S E O,D NV 0 1 0 0 1 2 A
125 801411 2133/06 Saraswati f H MN E D NV 0 0 0 0 1 1 A
126 801558 2154/06 Ethiraj m H,M MD A,N,S C,L L G,D,GU 2A NV 0 1 2 0 1 4 B B Y A
127 801234 1121/O6 Viswan m H,M MD N L N NV 1 1 0 0 0 2 A
128 793487 1411/06 Muniappan m M MD L MS NV 0 1 0 2 2 5 B
129 794321 1572/06 Sivan m H,M MD L E V,PHTG OV 3 V 0 2 2 0 1 5 B B EST
130 795038 1552/06 Sundar rajan m H MN L G NV 0 0 0 0 1 1 A
131 792663 1533/06 Shyam m H MN L,O L O,G,D NV 0 0 2 2 1 5 B
132 794298 1543/06 Saraswathi f M MD E GU 2A NV 0 2 0 0 1 3 B A
133 794294 1581/06 Sarojini f M MD C L G,GU 2A NV 0 2 2 0 1 5 B B A
134 795627 578+C170/0Archana f H MN O E N NV 0 0 2 0 0 2 A
135 795793 1648/06 Laxmi f H,bleeding pr MD L O,D NV 1 1 0 0 1 3 B B
136 795347 1665/06 Munusamy m H MN N O E G,D NV 0 0 2 0 1 3 B Y
S.
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137 796637 1727/06 Sakti m H,M MS A,S O E G,D,DU 2A NV 0 2 2 0 1 5 B
138 796432 1738/06 Nagaraj m H MN E G NV 0 1 0 0 1 2 A
139 796263 1696/06 Velayudhan m bleeding pr MN E N NV 0 0 0 0 0 0 A
140 796988 1778/06 Devaraj m H,M MD N,S C,O E GU 2B NV 0 2 2 2 1 7 C B A Y A
141 796645 1728/06 Gajalaxmi f H MN N O E O NV 1 1 2 2 1 7 C Y
142 797255 1634/06 Jeeva f H MN E N NV 0 0 0 0 0 0 A
143 796678 1778/06 Pandian m M MD A,S L O,G,D,GU 2A NV 0 0 0 0 1 1 A A
144 797318 1886/06 Jagannivas m H,M MD L L V,PHTG,PHTD GOV1 3 V 0 2 3 2 1 8 C B EVL Y EVL D
145 797704 1787/06 Kartik m H MN L O,D NV 0 0 0 0 1 1 A
146 798313 1888/06 Periyanayaki f M MD E GU 2A NV 0 0 0 2 1 3 B A Y A
147 798368 1848/06 Paul m H MN A,S L G,D NV 0 0 0 0 1 1 A
148 798239 1848/06 Visalakshi f M MD E V,PHTG,PHTD GOV2 3 V 0 2 2 0 1 5 B B EST
149 791300 1902/06 Srimati f H MN R L H,D NV 0 0 3 0 1 4 B
150 798808 1908/06 Chinnammal f H MN L N NV 0 0 0 0 0 0 A
151 799240 1900/06 Venkateswaran m M MD N E G,GOO NV 1 1 0 0 1 3 B
152 799218 1966/06 Kamalakannan m H MD L ,PHTG GOV2 3 V 0 2 2 0 1 5 B B EST
153 798630 1307/06 Krishnan m H MN B L L V OV 2 V 0 0 0 2 1 3 B B EST
154 799497 1916/06 Selvam f H MN E N NV 0 1 0 0 0 1 A
155 799400 1041/06 Vijayakumar m H MN S E N NV 0 0 0 0 0 0 A
156 799920 1145/06 Madavan m H MN E G NV 0 1 0 0 1 2 A
157 799742 1998/06 Santosh m H MD L N NV 0 1 0 0 1 2 A
158 799428 3824/05 Jaya f M MD A L L V OV 2 V 0 1 2 0 1 4 B B EST
159 800778 2103/06   Kalaiselvan          f H MN E O,G,D NV 0 0 0 0 1 1 A
160 800386 2160/06 Muthuvel m H,M MD A L G,D NV 0 2 0 0 1 3 B Y
161 769844 2070/06 Manimalai f H,M MD E H,O  NV 0 1 0 0 1 2 A
162 800976 2007/06 Velu m H,M MD A L O,D NV 0 1 0 0 1 2 A
163 801419 2144/06 Sumati f H MN E D NV 0 0 0 0 1 1 A
164 801555 2155/06 Govindaraj m H,M MD A,N C,O L G,D NV 0 1 2 0 1 4 B Y
165 811775 4325/04 Jeevarathinam m M MD E V GOV2 3 V 0 2 3 2 1 8 C B EST Y EST
166 812824 3002/06 Gopu m H,M MD E O,G NV 0 2 0 0 1 3 B
167 812136 2997/06 Sheikh meeran m H,M MD L L V,PHTG GOV2 3 V 1 2 2 2 1 8 C B EST Y
168 786670 2734/06 Shankaran m H MN N E G,DU 2A NV 1 1 0 0 1 3 B A
169 812576 2961/06 Subaida f H MN S L G NV 0 1 0 0 1 2 A
170 812050 2956/06 Laxmi f H MN A L L V,PHTG OV 2 V 0 2 2 2 1 7 C EST EST
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171 812344 2922/06 Arumugam m H,M MS B,N E O NV 0 2 0 2 2 6 C Y
172 814115 2982/06 Raja m H MN B,A L O,G,D NV 0 0 0 0 1 1 A
173 813273 3013/06 Shanmugam m H MN A,N E G NV 1 1 0 0 1 3 B Y
174 814911 3022/06 Ramani f H MN N L V OV 2 V 0 1 2 0 1 4 B EST
175 815664 3195/06 Shankar m H,M MD B,S L L GU 2A NV 0 2 2 2 1 7 C B A Y A
176 816452 4451/06 Abdul musharaf m H,M MS L V,PHTG GOV2 3 V 0 2 3 0 1 6 C B EVL Y EVL
177 818088 3390/06  Natarajan m H,M MD E G,D NV 1 2 0 0 1 4 B Y
178 816832 3337/06 Kalipillai m M MD N,S L DU 1B NV 1 1 0 2 1 5 B A Y A
179 818377 3385/06 Devika f H MN L N NV 0 0 0 0 0 0 A
180 818375 3260/06 Naveen m H MD L L MS NV 0 2 0 2 2 6 C B
181 15083 3399/06  Rekha f H,M MD E N NV 0 0 0 0 0 0 A
182 812928 2272/06 Paryal f H, MN B,N L GU 2A NV 0 0 0 0 1 1 A A
183 818934 3373/06  Manonmani f H MN E N NV 0 0 0 0 0 0 A
184 819158 3455/06 Govindaraj m H MN N L P NV 1 0 0 0 1 2 A
185 819473 1235/06 Gopinath m H MN C E #NAME? NV 0 0 0 0 1 1 A
186 819483 3353/06 Ravi m H MD A L O NV 0 1 0 0 1 2 A
187 819924 3519/06 Subhash m H,M MD A L G NV 0 1 0 0 1 2 A
188 818085 3369/06 Abdul Jaffer m H MD L E V,PHTG,PHTD OV 1 V 0 1 2 2 1 6 C B
189 819415 3484/06 Sukumar m H,M MD L O,G,D NV 0 1 0 0 1 2 A
190 819924 3519/06 Subhash m H,M MD A,S L DU 1B NV 0 1 0 2 1 4 B A
191 820269 3563/06  Laxmi f H<M MD L V,PHTG OV 2 V 0 2 2 0 1 5 B B EST
192 820650 3456/06 Saravanan m H,M MN B L L N NV 0 0 2 0 0 2 A
193 819406 3483/06 Rajamani m H,M MD A L L V,PHTG OV 2 V 0 2 2 0 1 5 B EST
194 820624 2245/06 Dhanalaxmi f H,M MD S L V,PHTG GOV2 3 V 0 2 0 0 1 3 B B EVL
195 818941 3642/06 Sivalingam m H MN O L O NV 1 0 2 0 1 4 B
196 821572 3661/06 Bhaskaran m H MN N C,O E G NV 0 0 2 0 1 3 B
197 822073 3668/06 Srinivasan m H MN E G,D NV 0 0 0 0 1 1 A
198 821863 3685/06 Kaliyaperumal m H MN S E O,G,D NV 0 0 0 0 1 1 A
199 821128 3626/06 Annamalai m H MN A E O,G,D NV 1 0 0 0 1 2 A
200 822870 2501/05 Kuppan m H MN L O,GOO NV 0 0 0 0 1 1 A
201 823075 3769/06 Selvaraj m H MN E G NV 1 1 0 0 1 3 B
202 823150 3761/06 Kasinath m H MD A L G NV 0 1 0 0 1 2 A
203 823798 3796/06 Veeramuthu m H,M MD N E G,D NV 0 1 0 0 1 2 A
204 823261 3804/06 Chakravarthi m H,M MD L L V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EVL
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205 823082 3801/06 Natesan m H,m MS N,S L DU 3 NV 1 2 0 2 1 6 C B
206 822259 3770/06 Manohar m M MD L G NV 0 2 0 0 1 3 B
207 822597 3777/06 Mohammed m H,M MD N,S E G,D,DU 3 NV 0 1 0 0 1 2 A
208 821108 3762/06 Murugan m H MN E O,G NV 0 0 0 0 1 1 A
209 823929 3821/06 Usman Ali m H,M MD L G NV 0 1 0 0 1 2 A
210 827382 3801/06 Natesan m H,M MD N E G,D NV 1 2 0 0 1 4 B Y
211 820555 3821/06 Vasanthi f M MD O L DU 2B NV 0 2 2 2 1 7 C B A Y A
212 824091 3766/06 Ramachandran m H MD E V,PHTG OV 2 V 0 2 2 0 1 5 B EST
213 824494 3884/06 Karunanidhi m H, MN L E V,PHTG GOV1 3 V 0 2 2 2 1 7 C B EVL Y EVL
214 824672 3814/06 Sundaram m H MN A L G NV 0 0 0 0 1 1 A
215 824661 3882/06 Ramesh m H, M MD S L L DU 2A NV 0 2 0 2 1 5 B B A
216 824666 3801/06 Anjana f M MD L G NV 0 1 0 0 1 2 A
217 825036 2955/06 Rasheed m H MN S O E G,D,GU 3 NV 1 1 2 0 1 5 B
218 825097 3319/06 Selvan m H,M MD L L V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EVL
219 825214 3762/06 Murugan m H MN E V,PHTG GOV1 3 V 0 1 2 0 1 4 B B EVL
220 825295 3914/06 Subramani m M MN E G NV 0 0 0 0 1 1 A
221 825502 4037/06 Muthaiah m m MD S O L G,DU 3 NV 1 1 2 0 1 5 B
222 825908 4054/06 Pennciliah m M MD A L L V,PHTG GOV2 3 V 0 2 2 2 1 7 C B EVL
223 824948 3942/06 Anjalai f H, M MD O L G NV 1 1 2 0 1 5 B
224 826409 3896/06 Rani f H MN E N NV 0 1 0 0 0 1 A
225 826382 3680/02 Ilangovan m H,m MD B L L V,PHTG OV 3 V 0 2 3 2 1 8 C B EST Y EST D
226 826621 4098/06 Rajendran m H MN A L L V,PHTG OV 2 V 0 1 2 0 1 4 B EST
227 827062 4021/06 Gomati f M MD C E G NV 0 2 2 0 1 5 B
228 826910 4122/06 Babu m H MN L G,D NV 0 0 0 0 1 1 A
229 826095 4119/06 Ganesan m H MD L O,G,D NV 2 2 0 0 1 5 B
230 827378 4138/06 Palani m M MD B,S L O,G,DU 1B NV 0 2 0 2 1 5 B B A
231 827533 3455/06 Gowndan m H,M MD L MS NV 1 2 0 2 2 7 C Y
232 827765 1570/06 Abhirami f H, MD E V OV 3 V 0 2 0 2 1 5 B B EST
233 825913 3924/05 Narayana moorty m H MD B,SU L L V,PHTG GOV1 3 V 0 2 2 0 1 5 B B EVL
234 827840 4229/06 Ganesan m H,M MD A L L MS NV 0 2 2 2 2 8 C B Y
235 828498 4201/06 Krishnan m H, M MS SU L GJ,G NV 0 2 0 0 1 3 B
236 829804 4271/06 Jeevita f H MN E G NV 0 0 0 0 1 1 A
237 824655 4225/06 Kumar m M MD A,S L G,D,GU 2C NV 0 2 0 0 1 3 B B
238 829748 4262/06 Annammal f H MN L O,G,D NV 1 0 0 0 1 2 A
S.
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239 829392 4325/06 Mannankatti m H MN B,C E G NV 0 1 0 0 1 2 A
240 829717 4330/06 Pandurangan m H MD B,S L G,D,GU 2C NV 0 1 0 0 1 2 A
241 829442 3824/06 Jayalakshmi f H,M MS A,B L E V OV 3 V 0 2 2 2 1 7 C B Y EVL
242 828854 4269/06 Saravanan m H MN L O,G,D NV 0 0 0 0 1 1 A
243 830334 2662/05 Krishnaveni f H MN B E O,G,D NV 0 0 0 1 1 A
244 830006 3668/06 Srinivasan m H MD B L DU,GOO 2C NV 0 1 0 1 2 A
245 830332 4228/06 Kumaran m H MN S C E G,D NV 0 0 2 0 1 3 B Y
246 825913 3928/05 Narayanan m H MD L V,PHTG GOV1 3 V 0 1 2 2 1 6 C B EVL
247 828922 3909/06 Sittrarasan m H MN B,A L V GOV2 3 V 0 1 2 0 1 4 B B EVL
248 830571 4375/06 Sampath m M MD A,S E G,DU 2B NV 0 2 0 2 1 5 B A
249 830682 4373/06 Papasami m H,M MD S L GU 2C NV 1 2 0 0 1 4 B
250 830820 4331//06 Saktivel m H MN N E G,D NV 0 0 0 0 1 1 A
251 830877 4370/06 Gunasekar m H MD N L G NV 0 1 0 0 1 2 A
252 830819 2811/05 Palani m H MD N L L V,PHTG OV 2 V 0 2 2 0 1 5 B B EST
253 831178 4417/06 Dakshinamoorthy m H,M MD N E G,D NV 0 1 0 0 1 2 A
254 831180 1648/06 Sundar m H,M MS B E V,PHTG OV 2 V 0 2 0 2 1 5 B
255 830900 1656/06 Subadhra f M MD O E G NV 0 2 2 0 1 5 B
256 831358 439/06 Ethiraj m H MN S E G,DU 2C NV 1 0 0 0 1 2 A
257 830921 4419/06 Nathan m H,M MS O E DU 2B NV 0 2 2 2 1 7 C B A Y A
258 831550 4478/06 Visalakshi f H,M MD N L G,D,GU 2C NV 0 2 0 0 1 3 B
259 830780 4380/06 Chinnaponnu f H, M MS L L V,PHTG GOV2 3 V 0 2 3 0 1 6 C B EVL Y EVL
260 831797 4456/06 Saroja f H, M MN N E MS NV 0 0 0 2 2 4 B
261 831983 4315/06 Devaki f H MN A,S E G NV 0 0 0 1 1 A
262 831882 4454/06 Lourdusami m H,M MD SU L O,G,D NV 0 1 0 1 2 A
263 831443 4434/06 Munusamy m H,M MD L A NV 0 1 2 1 4 B B
264 831089 4394/06 Vijayan m M MD L E V V 0 2 2 0 1 5 B B
265 831812 4490/06 Manimozhi f H MD L L V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EST
266 832582 4414/06 Stella f H MN N L G NV 0 1 0 0 1 2 A
267 832587 4406/05 Ravi m H MN A,S L E G NV 0 1 2 0 1 4 B
268 832485 4498/06 Panjalai f H MN O L O,G,D NV 0 0 2 0 1 3 B
269 830058 4380/06 Amir basha m M MD A L E V OV 2 V 0 2 2 0 1 5 B B EST
270 831172 4420/06 Chinnaiya m H MD N,S R L DU 2B NV 2 2 3 2 1 10 C A Y A
271 833039 4538/06 Kamaludeen m H MN A,S L E V OV 2 V 1 2 2 2 2 9 C B Y EST
272 833403 4545/06 Dayalan m H,M MD A,S L E V,PHTG OV 2 V 0 2 2 0 1 3 B B EST
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273 833734 4323/06 Maharun beevi f H MD L L V,PHTG GOV2 3 V 0 2 3 2 1 8 C B EVL
274 833197 4625/06 Selvi f H MN N O E H,O,D NV 0 0 2 0 1 3 B
275 834056 4616/06 Vasu m H MN C L O,G,D NV 0 0 2 0 1 3 B
276 834163 4166/06 Dhanalaxmi f H MN E G NV 1 1 0 0 1 3 B
277 834110 4623/06 Deepa f H MN C E G NV 0 0 0 0 1 1 A
278 832200 4620/06 Kanniappan m H MN S L DU 2A NV 0 0 0 2 1 3 B A
279 834699 4464/06 Mahalaxmi f M MD L DU 2B NV 0 1 0 2 1 4 B A
280 834700 4580/06 Siraj m H,M MD N E N NV 0 1 0 0 0 1 A
281 834721 4639/06 Murugan m H MN L V OV 2 V 0 1 2 0 1 4 B B EST
282 835298 4604/06 Baby f H MN C L G,D NV 0 0 2 0 1 3 B
283 835283 4723/06 Vasanta f H MN N E G,D NV 0 0 0 0 1 1 A
284 834744 4706/06 Kasiammal f H MN O L G,D NV 0 0 2 0 1 3 B
285 835193 4730/06 Vijayalaxmi f H MN A,N L W NV 0 0 0 0 1 1 A
286 835186 4691/06 Srinivasan m H MD N,S L G,D,GU 2C NV 0 1 0 0 1 2 A
287 835201 4692/06 Rajkumar m H,M MS L V,PHTG GOV2 3 V 0 2 0 0 1 3 B B EVL
288 835881 46826/06 Murugesan m H MN A,S E G,D NV 0 0 0 0 1 1 A
289 835883 4595/06 Kumari f H MD N L N NV 0 1 0 0 0 1 A
290 836176 4752/06 Raman m H,M MD S E BD,DU 3 NV 1 1 0 0 1 3 B B
291 834484 4655/06 Soundararajan m H,M MD N E V,PHTG,PHTD GOV2 3 V 0 2 2 2 1 7 C B EST Y
292 836382 4767/06 Masila m H MD L DU 2C NV 0 2 0 0 1 3 B
293 836786 4813/06 Murugan m H MN A,S E G NV 0 0 0 0 1 1 A
294 836988 4484/06 Sahadevan m H MN E G,D NV 0 0 0 0 1 1 A
295 837537 4852/06 Ramesh m H,M MD N,S L DU 1B NV 0 2 0 2 1 5 B B A
296 837540 4851/06 Sindhuja f M MN N E G,D NV 0 1 0 0 1 2 A
297 837592 4857/06 Senthil kmar m H,M MD N,S L L G,DU 2A NV 0 2 2 2 1 7 C A Y A
298 837567 4858/06 Kuppusamy m H MS A,S L E V,PHTG OV 2 V 0 2 2 2 1 7 C B Y EST
299 837260 4836/06 Muniammal f H,M MD N L G NV 0 1 0 0 1 2 A
300 838203 4721/06 Loganayaki f H,M MD L G,DU 2B NV 0 1 0 2 1 4 B B A Y A
301 838054 4922/06 Gopal m H MD S L GJ,G,D NV 0 2 0 0 1 3 B
302 838357 4932/06 Kalaiselvan m H MD N E DU,GOO 2B NV 0 2 0 2 1 5 B B Y A
303 838785 4919/06 Luminachandra f H MN E G NV 0 0 0 0 1 1 A
304 838786 4481/06 Bavani f H,M MD E G NV 0 1 0 0 1 2 A
305 839432 4881/06 Gnanamary f H MN E G,D NV 0 0 0 0 1 1 A
306 838781 4970/06 Muthu m H MN N,A,S L DU 2B NV 0 0 0 2 1 3 B A
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307 839443 4887/06 Balu m H MD N,S E GU 2C NV 0 2 0 0 1 3 B
308 839441 4937/06 Menaka f H MD N L G,D NV 0 2 0 0 1 3 B
309 838359 4944/06 Kannabiran m H MD L G,D NV 1 1 0 0 1 3 B
310 839261 4960/06 Selvakumar m M MD L G,D NV 0 1 0 0 1 2 A B
311 840236 5063/06 Alagesan m H MN A E G,GU 3 NV 0 0 0 0 1 1 A
312 839143 4993/06 Anjamma f H MS L G,D NV 0 2 0 2 1 5 B
313 840280 5064/06 Sakunthala f H MD L DU 2B NV 0 1 0 2 1 4 B B A
314 839862 5109/06 Ramesh m H,M MD A E G NV 0 2 0 0 1 3 B
315 840390 5131/06 Raja m H,M MN L G NV 0 0 0 0 1 1 A
316 840234 5096/06 Sukumar m H MD A L L G NV 0 1 2 0 1 4 B
317 839120 3319/06 Selvi f H MN E G NV 0 0 0 0 1 1 A B
318 840964 5085/06 Vennila f H MD L GJ,GU 2C NV 0 2 0 2 1 5 B B
319 840869 5088/06 Varadan m H MN A L V,PHTG GOV2 3 V 1 1 2 2 1 7 C B EVL EVL
320 841044 5138/06 Sekar m H MN A E V,PHTG GOV2 3 V 0 1 2 0 1 4 B B EVL
321 841566 5182/06 Beena mary f H MN N L E V,PHTG GOV2 3 V 0 2 2 2 1 7 C EST EST
322 841454 5146/06 Ismail m H, bleeding PR MD A,S L E V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EVL
323 841873 5204/06 Ramesh m H MN L L V,PHTG OV 2 V 0 1 2 0 1 4 B B EVL
324 842635 4336/05 Rajendran m H,M MD L E V,PHTG OV 2 V 0 2 2 2 1 7 C EST EST
325 842673 4422/06 Rajesh kumar m H MN A E V,PHTG OV 2 V 0 2 0 0 1 3 B EST
326 842714 5217/06 Krishnan m H MD SU L L V,PHTG OV 3 V 0 2 2 0 1 5 B Y EVL
327 842615 5257/06 Selvaraj m H MN C E V,PHTG OV 1 V 0 1 0 0 1 2 A
328 840446 5120/06 Gnanasekaran m M MD L L V,PHTG GOV2 3 V 0 1 2 2 1 6 C B EST
329 843630 5323/06 Moorty m H,M MD B L E V,PHTG GOV2 3 V 0 2 2 0 1 5 B B EST
330 842999 5267/06 Ponnusamy m H MN A L L V,PHTG GOV2 3 V 0 1 2 0 1 4 B EST
331 843646 5321/06 Banumathy f H,M MD L V,PHTG OV 2 V 0 2 2 0 1 5 B B EST
332 843519 5332/06 Guhan m H MN A,S E V,PHTG OV 2 V 0 1 0 0 1 2 A
333 844265 5367/06 Mookayee f H MD L L V,PHTG IGV1 V 1 2 2 0 1 6 C B
334 844308 5371/06 Lakshmi f H,M MD N E V,PHTG OV 2 V 0 2 0 2 1 5 B B EST EST
335 844808 5241/06 Dhanalaxmi f H MN L V,PHTG OV 2 V 0 1 0 0 1 2 A
336 844028 5339/06 Jothi f H MN A L E V,PHTG OV 2 V 0 1 2 0 1 4 B EST
337 844345 5385/06 Viswanathan m H MN N C E V,PHTG OV 1 V 0 1 2 0 1 4 B
338 844748 5409/06 Kalidas m H MN N E V,PHTG GOV1 3 V 0 1 0 0 1 2 A B EVL
339 844744 5442/06 Guganraj m H MN N L V,PHTG OV 1 V 0 2 0 0 1 3 B B
340 845009 5462/06 Dayalan m H MD A L E V,PHTG OV 1 V 0 1 2 0 1 4 B B
S.
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341 845895 5074/06 Minnala f H MN L V,PHTG OV 1 V 1 1 2 0 1 5 B B
342 846210 5512/06 Rajkumar m H MD C E O,G,D NV 0 1 0 0 1 2 A
343 846156 5511/06 Indira f M MD A L N NV 0 0 0 0 0 0 A
344 846135 5510/06 Gowri f M MD A L N NV 0 0 0 0 0 0 A
345 846668 5517/06 Rathinam m H,M MD N E GU 3 NV 1 2 0 0 1 4 B
346 846760 5515/06 Chinnaponnu f H MN N C E G,D NV 1 1 2 0 1 5 B B
347 846612 5518/06 Kodeeswaran m H,M MD B E G NV 0 1 0 0 1 2 A
348 847008 5533/06 Subramani m H MN A E G NV 0 0 0 0 1 1 A
349 845102 5548/06 K+D87rishnaraj m H MN N L O,D,GU 3 NV 0 0 0 0 1 1 A
350 847554 5554/06 Muthuraman m H,M MD N,S E O,D,DU 3 NV 0 1 0 0 1 2 A
351 847584 5578/06 Kanniammal f H,M MD L G,D NV 1 1 0 0 1 3 B
352 847997 5588/06 Natarajan m H,M MD N E G NV 0 2 0 0 1 3 B
353 848103 5613/06 Ramamoorthy m H,M MN N E O,G NV 1 1 0 0 1 3 B
354 896106 5617/06 Dhanasekhar m H,M MD N,S C E G,D,DU 3 NV 0 1 2 0 1 4 B
355 848300 5658/06 Venugopal m H,M MD L L G NV 0 1 2 0 1 4 B
356 849439 5666/06 Mahalaxmi f H MN L ,DU 3 NV 0 1 0 0 1 2 A
357 849437 5564/06 Vinayagam m H MN A E G NV 0 0 0 0 0 0 A
358 849674 5709/06 Jamesh babu m H MN E G+L203 NV 0 0 0 0 0 0 A
359 849322 5736/06 Vasanta f H MN N C.O E MS NV 1 0 2 2 1 6 B
360 849344 5703/06 Loganathan m H MN E MS NV 0 1 0 2 2 5 B B
361 850228 5777/06 Roshini f H MN E H,G,D NV 0 1 0 0 1 2 A
362 850925 5839/06 Selvaraj m H MN N L MS NV 0 1 0 2 2 5 B
363 850806 5837/06 Kallel m M MD A,N O L MS NV 0 2 2 2 2 8 C B
364 850819 5790/06 Govindaraj m H MD S E MS NV 0 2 0 2 2 6 C B
365 850748 5845/06 Saraswati f H MN E MS NV 0 2 0 2 2 6 C B
366 852197 5917/06 Prakash m H,M MD C E G,D NV 0 2 0 0 1 3 B B
367 850761 5858/06 Subramani m H,M MD E O,G,D NV 0 2 0 2 1 5 B
368 852046 5943/06 Kandasamy m M MD E G NV 1 1 0 0 1 3 B
369 852831 5761/06 Malini f H MN L GU 2B NV 0 2 0 2 1 5 B B
370 853196 1197/06 Deepa f H,M MD A L L V,DU 3 NV 0 2 2 0 1 5 B B
371 852478 3202/06 Kavita f H,M MD E G,DU 3 NV 0 1 0 0 1 2 A
372 853791 6060/06 Govindan m H,M MD A L G,D NV 0 1 0 0 1 2 A
373 854027 5407/06 Kannivel m H MN A,S L G,D NV 0 0 0 0 1 1 A
374 853878 6049/06 Manoharan m H MN A,S E O,G,D NV 0 0 0 0 1 1 A
S.
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375 853892 6073/06 Sivaprakasam m H MN A E DU 1B NV 1 1 0 2 1 5 B B Y A
376 854240 55/06 Santhi f H,M MD L L DU 2B NV 0 2 2 2 1 7 C B A Y A
377 854610 2106/06 Bharati f H MD S E PHTG NV 0 2 0 0 1 3 B
378 854390 6079/06 Ramesh m H MD S E O,G,D,DU 3 NV 0 2 0 0 1 3 B
379 853109 6036/06 Indrani f H MN E O,G,DU 3 NV 0 0 0 0 1 1 A
380 855701 6198/06 Ramaiah m H MN S L H,O,G NV 0 0 0 0 1 1 A
381 855402 6171/06 Balu m H MD A,B,S L E G,DU 2C NV 0 2 2 0 1 5 B B
382 855688 6047/06 Alagu m H MD B,S L G,DU,GU 3 NV 0 1 0 0 1 2 A
383 851421 6057/06 Gnanasekaran m H MN A,S L E O,DU 2B NV 0 1 2 0 1 5 B B A
384 855752 6199/06 Krishnan m H MD S E O,DU,A 1B NV 0 2 0 0 1 3 B B A
385 856554 6277/06 Kuppammal f H,M MD E O,DU 1B NV 0 2 0 0 2 4 B B A
386 856614 6291/06 Nisha f H MN L O,G NV 0 1 0 0 1 2 A
387 857173 6352/06 Dhanona f H MN E A NV 0 1 0 0 1 2 A
388 857415 6313/06 Subramani m H,M MD N E O NV 0 1 0 0 1 2 A
389 857847 6414/06 Annammal f H MN N E O NV 1 1 0 0 1 3 B B
390 857948 6385/06 Podimal m H MN A L G NV 0 1 0 0 1 2 A
391 857860 6422/06 Jothi f H MN L O NV 0 2 0 2 1 5 B
392 857555 4998/06 Kubendran m H,M MD B E DU 1B NV 0 2 0 2 1 5 B A Y A
393 858400 6447/06 Dillibabu m H MN N,S E MS NV 0 1 0 2 1 4 B
394 858786 6493/06 Mohan m H MD A,S L L G,D NV 0 1 2 2 1 6 C B Y
395 859660 6525/06 Rukmani f H MN L G NV 0 0 0 0 1 1 A
396 858389 6585/06 Sonam f H MD L L G,D NV 0 1 2 0 1 4 B
397 859570 6574/06 Murugan m H MD L G,D,DU 2C NV 0 2 0 2 1 5 B B
398 860610 6628/06 Rajalaxmi f H,M MN O L G,D NV 1 0 2 0 1 4 B
399 860559 6639/06 Deenadayalan m H MN E DU 1B NV 1 1 0 0 1 3 B A Y A
400 861101 6684/06 Yesurathinam m H MN N E G NV 0 0 0 0 1 1 A
401 861239 6475/06 Gopi m H MD S L DU 1B NV 0 2 0 2 1 5 B B
402 860988 1378/05 Kalpana f H,M MD E A NV 0 2 0 2 1 5 B B
403 860270 6775/06 Ponmudi m H MN A,S E G,DU 2C NV 0 2 0 2 1 5 B B
404 862031 6776/06 Raja m H MN A,S L E G,GU 1B NV 0 1 2 0 1 4 B A Y A
405 862029 6741/06 Pari m H MN L G,GU,DU 2B NV 0 1 0 2 1 4 B A
406 861234 3560/03 Thayal nayaki f H,M MD E O,G NV 0 1 0 0 1 2 A B
